<PAGE> 1
SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
<TABLE>
<S> <C>
[X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission
Only (as permitted by Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-2.
</TABLE>
Lifequest Medical, Inc.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-12.
(1) Title of each class of securities to which transaction applies:
------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
------------------------------------------------------------------------
(5) Total fee paid:
------------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
------------------------------------------------------------------------
(3) Filing Party:
------------------------------------------------------------------------
(4) Date Filed:
------------------------------------------------------------------------
<PAGE> 2
LIFEQUEST MEDICAL, INC.
LIFEQUEST MEDICAL, INC.
12961 Park Central, Suite 1300
San Antonio, Texas 78216
Telephone: (210) 495-8787
January ____, 1999
Dear Stockholder:
On behalf of the Board of Directors, I cordially invite you to attend a
Special Meeting of the Stockholders of LifeQuest Medical, Inc. ("LifeQuest" or
the "Company"). The Special Meeting will be held Thursday, February 25, 1999, at
1:00 p.m. E.D.T. at the Company's Atlanta offices, located at Fulton 400
Corporate Center, Suite 700, Roswell, Georgia. The formal Notice of Special
Meeting is set forth in the enclosed material.
At the Special Meeting you will be asked to consider and vote upon the
approval and adoption of a Plan of Merger and Acquisition Agreement (the "Merger
Agreement") which would merge Dexterity Incorporated ("Dexterity") with and into
LifeQuest (the "Merger"). As part of the consideration for the Merger, the
stockholders of Dexterity, other than LifeQuest, will receive 3,000,000 shares
of LifeQuest Common Stock. In addition, simultaneous with the effectiveness of
the Merger, LifeQuest will change its name to Dexterity Surgical, Inc. Following
the meeting, stockholders will have the opportunity to ask questions and comment
on the operations of LifeQuest Medical, Inc.
YOUR BOARD OF DIRECTORS HAS APPROVED THE TERMS OF THE MERGER AGREEMENT
AND THE TRANSACTIONS CONTEMPLATED THEREBY AND RECOMMENDS THAT YOU VOTE FOR THE
PROPOSAL TO APPROVE AND ADOPT THE TERMS OF THE MERGER AGREEMENT AND THE
TRANSACTIONS CONTEMPLATED THEREBY. In considering this recommendation, you
should review carefully all the information contained in the attached Proxy
Statement, including the Appendices thereto.
YOUR VOTE AT THE SPECIAL MEETING IS EXTREMELY IMPORTANT. WHETHER OR NOT
YOU INTEND TO BE PRESENT AT THE SPECIAL MEETING, YOU ARE URGED TO ACT PROMPTLY
IN COMPLETING, SIGNING AND DATING THE ENCLOSED PROXY SOLICITED BY YOUR BOARD OF
DIRECTORS AND RETURNING IT IN THE ENVELOPE PROVIDED. IF YOU ATTEND THE SPECIAL
MEETING, YOU MAY VOTE YOUR SHARES IN PERSON, WHETHER OR NOT YOU HAVE PREVIOUSLY
SUBMITTED A PROXY.
We appreciate your investment in LifeQuest Medical, Inc. and urge you
to return your proxy card as soon as possible. We look forward to greeting
personally those stockholders who are able to be present at the meeting.
On behalf of the Board of Directors,
Richard A. Woodfield
President and Chief Executive Officer
<PAGE> 3
LIFEQUEST MEDICAL, INC.
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
NOTICE IS HEREBY GIVEN that a Special Meeting of Stockholders of
LifeQuest Medical, Inc. (the "Company") will be held on Thursday, February 25,
1999, at 1:00 p.m., E.D.T., at the Company's Atlanta offices, located at Fulton
400 Corporate Center, Suite 700, Roswell, Georgia, for the following purposes:
(1) To consider and vote upon a proposal to approve and adopt
the terms of the Plan of Merger and Acquisition Agreement dated December 18,
1998 between the Company and Dexterity Incorporated; and
(2) To consider and act upon any other matter which may
properly come before the meeting or any adjournment thereof. The Board of
Directors is presently unaware of any other business to be presented to a vote
of the stockholders at the Special Meeting.
Information with respect to the above proposal is set forth in the
Proxy Statement that accompanies this Notice.
The Board of Directors of the Company has fixed the close of business
on January 27, 1999, as the record date for determining stockholders entitled to
notice of and to vote at the meeting. A complete list of the stockholders
entitled to vote at the meeting will be maintained at the Company's principal
executive offices during ordinary business hours for a period of ten (10) days
prior to the meeting. The list will be open to the examination of any
stockholder for any purpose germane to the meeting during this time. The list
will also be produced at the time and place of the meeting and will be open
during the whole time thereof.
By Order of the Board of Directors,
RICHARD A. WOODFIELD
President and Chief Executive Officer
San Antonio, Texas
January _____, 1999
IMPORTANT
YOU ARE CORDIALLY INVITED TO ATTEND THE SPECIAL MEETING IN PERSON. EVEN
IF YOU PLAN TO BE PRESENT, PLEASE MARK, SIGN, DATE AND RETURN THE ENCLOSED PROXY
AT YOUR EARLIEST CONVENIENCE IN THE ENVELOPE PROVIDED, WHICH REQUIRES NO POSTAGE
IF MAILED IN THE UNITED STATES. IF YOU ATTEND THE MEETING, YOU MAY VOTE EITHER
IN PERSON OR BY YOUR PROXY.
<PAGE> 4
LIFEQUEST MEDICAL, INC.
PROXY STATEMENT
SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON FEBRUARY 25, 1999
GENERAL INFORMATION
This Proxy Statement and the accompanying proxy are furnished to the
stockholders of LifeQuest Medical, Inc., a Delaware corporation ("LifeQuest" or
the "Company"), in connection with the solicitation by the Board of Directors of
proxies for use at a Special Meeting of Stockholders (the "Special Meeting" or
"Meeting") to be held on Thursday, February 25, 1999, at 1:00 p.m., E.D.T., at
the Company's Atlanta offices, located at Fulton 400 Corporate Center, Suite
700, Roswell, Georgia, and at any adjournment or postponement thereof, for the
purpose set forth in the foregoing Notice of Special Meeting of Stockholders.
Properly executed proxies received in time for the Meeting will be voted.
At the Special Meeting, stockholders are being asked to vote on a
proposal to approve the merger (the "Merger") of Dexterity Incorporated, a
Delaware corporation ("Dexterity"), with and into the Company pursuant to a Plan
of Merger and Acquisition Agreement dated December 18, 1998 between the Company
and Dexterity (the "Merger Agreement") and the issuance of Common Stock (as
defined herein) in connection therewith. If the Merger is consummated, LifeQuest
will be the surviving corporation and will change its name to Dexterity
Surgical, Inc. On December 18, 1998, the last trading date preceeding the public
announcement of the Merger, the high and low sales price of Common Stock were $1
15/16 and $1 9/16, respectively. Representatives from the Company's independent
public accountants, Arthur Andersen LLP, will be present at the Special Meeting.
Such representatives will be allowed to make a statement if they so desire, and
are expected to be available to take appropriate questions from stockholders.
A copy of the Merger Agreement, as amended, is set forth as Appendix A
to this Proxy Statement and is incorporated herein by reference. THE BOARD OF
DIRECTORS OF LIFEQUEST (THE "LIFEQUEST BOARD") HAS APPROVED THE MERGER AND
MERGER AGREEMENT. THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR THE
PROPOSAL TO APPROVE AND ADOPT THE MERGER AGREEMENT.
The securities of the Company entitled to vote at the Special Meeting
consist of shares of common stock, $.001 par value ("Common Stock"), and shares
of preferred stock, $.001 par value ("Preferred Stock"). At the close of
business on January 27, 1999 (the "Record Date"), there were outstanding and
entitled to vote 7,212,742 shares of Common Stock and 2,170 shares of Preferred
Stock. The holders of record of Common Stock or Preferred Stock on the Record
Date will be entitled to one vote per share.
This Proxy Statement is being mailed on or about January _____, 1999,
to the holders of record of Common Stock or Preferred Stock on the Record Date.
VOTING AND PROXY PROCEDURES
Properly executed proxies received in time for the Meeting will be
voted. Stockholders are urged to specify their choices on the proxy, but if no
choice is specified, eligible shares will be voted for the proposal to approve
and adopt the Merger. At the date of this Proxy Statement, management of the
Company knows of no other matters which are likely to be brought before the
Special Meeting. However, if any other matters should properly come before the
Special Meeting, the persons named in the enclosed proxy will have discretionary
authority to vote such proxy in accordance with their best judgment on such
matters.
If the enclosed form of proxy is executed and returned, it may
nevertheless be revoked by a later-dated proxy or by written notice filed with
the Secretary at the Company's executive offices at any time before the enclosed
proxy is exercised. Stockholders attending the Special Meeting may revoke their
proxies and vote in person. The Company's executive offices are located at 12961
Park Central, Suite 1300, San Antonio, Texas 78216.
<PAGE> 5
The holders of a majority of the total shares of Common Stock and
Preferred Stock issued and outstanding at the close of business on the Record
Date, whether present in person or represented by proxy, will constitute a
quorum for the transaction of business at the Special Meeting. The affirmative
vote of a majority of the total shares of Common Stock and Preferred Stock
outstanding and entitled to vote at the Special Meeting is required for the
approval of the proposal to approve and adopt the Merger Agreement and the
affirmative vote of a majority of the total shares of Common Stock and Preferred
Stock present in person or represented by proxy and entitled to vote at the
Special Meeting is required for the approval of any other matters as may
properly come before the Special Meeting or any adjournment thereof.
Abstentions are counted toward the calculation of a quorum, but are not
treated as either a vote for or against the proposal. An abstention has the same
effect as a vote against the proposal. Any unvoted position in a brokerage
account will be considered as not voted and will not be counted toward
fulfillment of quorum requirements.
The cost of solicitation of proxies will be paid by the Company. In
addition to solicitation by mail, proxies may be solicited by the directors,
officers and employees of the Company, without additional compensation (other
than reimbursement of out-of-pocket expenses), by personal interview, telephone,
telegram or otherwise. Arrangements will also be made with brokerage firms and
other custodians, nominees and fiduciaries who hold the voting securities of
record for the forwarding of solicitation materials to the beneficial owners
thereof. The Company will reimburse such brokers, custodians, nominees and
fiduciaries for reasonable out-of-pocket expenses incurred by them in connection
therewith.
OWNERSHIP OF COMMON STOCK
SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS AND MANAGEMENT
The following table sets forth as of January 12, 1999, certain
information with respect to the Company's Common Stock beneficially owned by
each stockholder known by the Company to be the beneficial owner of more than 5%
of the Company's Common Stock, each of its directors, each executive officer
named in the Summary Compensation Table contained in the Proxy Statement to the
Company's 1998 Annual Meeting of Stockholders and by all its directors and
executive officers as a group. Such persons have sole voting power and sole
dispositive power with respect to all shares set forth in the table unless
otherwise specified in the footnotes to the table.
<TABLE>
<CAPTION>
AMOUNT AND NATURE OF
NAME AND ADDRESS OF BENEFICIAL OWNER(1) BENEFICIAL OWNERSHIP PERCENT(2)
- -------------------------------------- -------------------- ----------
<S> <C> <C>
Renaissance Capital Group, Inc.(3)
8080 N. Central Expressway, Suite 210
Dallas, Texas 75206 .............................. 2,750,000 28.3%
Richard H. Klein(4) .............................. 597,750(5) 8.2%
16506 Strong Box
San Antonio, Texas 78247
William H. Bookwalter ............................ 326,780(6)(7) 4.5%
Kalford C. Fadem ................................. 220,000(8) 3.0%
Robert S. Fadem .................................. 208,000(9) 2.9%
Herbert H. Spoon(10) ............................. 201,904 2.8%
8 Otis Place
Verona, New Jersey 07044
Robert L. Evans .................................. 131,950(11) 1.8%
Randall K. Boatright, C.P.A ...................... 76,550(12) 1.1%
Robert B. Johnson ................................ 39,095(13) *
</TABLE>
-2-
<PAGE> 6
<TABLE>
<CAPTION>
AMOUNT AND NATURE OF
NAME AND ADDRESS OF BENEFICIAL OWNER(1) BENEFICIAL OWNERSHIP PERCENT(2)
- -------------------------------------- -------------------- ----------
<S> <C> <C>
Richard A. Woodfield (14) ........................ 30,000(15) *
Jeffrey H. Berg, Ph.D ............................ 29,500(16) *
Robert Pearson(17) ............................... 0(18) 0
David J. Collette, M.D.(19) ...................... 0 0
17 Inwood Autumn
San Antonio, Texas 78248
All executive officers and directors as a group
(nine persons, including the executive officers
and directors listed above) ...................... 1,061,875(7) (11) 14.2%
(15)(20)
</TABLE>
- ---------------
* Represents less than 1% of the issued and outstanding shares of Common
Stock.
(1) Except as otherwise noted, the street address of the named beneficial
owner is 12961 Park Central, Suite 1300, San Antonio, Texas 78216.
(2) Percentage is based on a total of 7,212,742 shares of Common Stock
issued and outstanding on January 12, 1999. (3) Represents 125,000
shares of Common Stock held by Renaissance Capital Growth & Income Fund
III, Inc. ("Renaissance Fund"), 750,000 shares of Common Stock issuable
upon conversion of convertible debentures held by Renaissance Fund,
125,000 shares of Common Stock held by Renaissance U.S. Growth & Income
Trust, PLC ("Renaissance Trust"), 750,000 shares of Common Stock
issuable upon conversion of convertible debentures held by Renaissance
Trust, 500,000 shares of Common Stock issuable upon conversion of
Preferred Stock held by Renaissance Fund and 500,000 shares of Common
Stock issuable upon conversion of Preferred Stock held by Renaissance
Trust. Renaissance Capital Group, Inc. ("Renaissance Group") is the
investment advisor to Renaissance Fund and Renaissance Trust and has
voting and dispositive power of the shares of Common Stock beneficially
owned by each of Renaissance Fund and Renaissance Trust.
(4) Mr. Klein resigned from his positions with the Company December 31,
1998.
(5) Includes 40,000 shares of Common Stock which Mr. Klein has the right to
acquire upon exercise of stock options.
(6) Includes 20,000 shares of Common Stock which Mr. Bookwalter has the
right to acquire upon exercise of stock options.
(7) Does not include 8,405 shares of Common Stock held by The 1997
Bookwalter Family Trust, of which Mr. Bookwalter serves as trustee. Mr.
Bookwalter disclaims beneficial ownership of such shares.
(8) Includes 40,000 shares of Common Stock which Mr. Fadem has the right to
acquire upon the exercise of stock options.
(9) Includes 40,000 shares of Common Stock which Mr. Fadem has the right to
acquire upon exercise of stock options. Represents shares of Common
Stock which Mr. Fadem shares voting and dispositive power.
(10) Mr. Spoon resigned from his positions with the Company effective March
9, 1998.
(11) Includes shares which Mr. Evans shares voting and dispositive power.
Includes 700 shares of Common Stock Mr. Evans has the right to acquire
upon the exercise of stock options.
(12) Includes 60,550 shares of Common Stock which Mr. Boatright has the
right to acquire upon the exercise of stock options.
(13) Includes 39,000 shares of Common Stock which Mr. Johnson has the right
to acquire upon the exercise of stock options.
(14) Mr. Woodfield was elected to the Board of Directors on May 19, 1998.
(15) Includes 10,000 shares of Common Stock which Mr. Woodfield has the
right to acquire upon the conversion of Preferred Stock.
(16) Represents shares of Common Stock which Dr. Berg has the right to
acquire upon the exercise of stock options. (17) Mr. Pearson was
elected to the Board of Directors on December 8, 1998. (18) Does not
include shares of Common Stock beneficially owned by Renaissance Group.
Mr. Pearson is an executive officer of the Renaissance Group and may be
deemed the beneficial owner of such shares. Mr. Pearson disclaims such
beneficial ownership.
(19) Dr. Collette resigned from his positions with the Company December 31,
1997.
(20) Includes 229,750 shares of Common Stock which executive officers and
directors have the right to acquire upon the exercise of options. Does
not include 201,904 shares of Common Stock held by Mr. Spoon or 597,750
shares of Common Stock beneficially owned by Mr. Klein.
-3-
<PAGE> 7
OWNERSHIP OF PREFERRED STOCK
SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS AND MANAGEMENT
The following table sets forth as of January 12, 1999, certain
information with respect to the Company's Preferred Stock beneficially owned by
each stockholder known by the Company to be the beneficial owner of more than 5%
of the Company's Preferred Stock, each of its directors, each executive officer
named in the Summary Compensation Table contained in the Proxy Statement to the
Company's 1998 Annual Meeting of Stockholders and by all its directors and
executive officers as a group. Such persons have sole voting power and sole
dispositive power with respect to all shares set forth in the table unless
otherwise specified in the footnotes to the table.
<TABLE>
<CAPTION>
AMOUNT AND NATURE OF
NAME AND ADDRESS OF BENEFICIAL OWNER(1) BENEFICIAL OWNERSHIP PERCENT(2)
- -------------------------------------- -------------------- ----------
<S> <C> <C>
Renaissance Capital Group, Inc.
8080 N. Central Expressway, Suite 210
Dallas, Texas 75206 ............................. 2,000(3) 92.2%
Richard A. Woodfield(4) .......................... 20 *
Robert Pearson(5) ................................ 0(6) 0%
Richard H. Klein(7) .............................. 0 0%
16506 Strong Box
San Antonio, Texas 78247
William H. Bookwalter ............................ 0 0%
Herbert H. Spoon(8) .............................. 0 0%
8 Otis Place
Verona, New Jersey 07044
Randall K. Boatright, C.P.A ...................... 0 0%
Kalford C. Fadem ................................. 0 0%
Robert L. Evans .................................. 0 0%
Jeffrey H. Berg, Ph.D ............................ 0 0%
Robert B. Johnson ................................ 0 0%
David J. Collette, M.D.(9) ....................... 0 0%
17 Inwood Autumn
San Antonio, Texas 78248
Robert S. Fadem .................................. 0 0%
All executive officers and directors as a group
(nine persons, including the executive officers
and directors listed above) ...................... 20 *
</TABLE>
- ------------------
* Represents less than 1% of the issued and outstanding shares of
Preferred Stock.
(1) Except as otherwise noted, the street address of the named beneficial
owner is 12961 Park Central, Suite 1300, San Antonio, Texas 78216.
(2) Percentage is based on a total of 2,170 shares of Preferred Stock
issued and outstanding on January 12, 1999.
(3) Represents 1,000 shares of Preferred Stock held by Renaissance Fund and
1,000 shares of Preferred Stock held by Renaissance Trust. Renaissance
Group is the investment advisor to Renaissance Fund and Renaissance
Trust
-4-
<PAGE> 8
and has voting and dispositive power with respect to the shares of
Preferred Stock owned by Renaissance Fund and Renaissance Trust.
(4) Mr. Woodfield was elected to the Board of Directors on May 19, 1998.
(5) Mr. Pearson was elected to the Board of Directors on December 8, 1998.
(6) Does not include shares of Preferred Stock beneficially owned by
Renaissance Group. Mr. Pearson is an executive officer of the
Renaissance Group and may be deemed the beneficial owner of such
shares. Mr. Pearson disclaims such beneficial ownership.
(7) Mr. Klein resigned from his positions with the Company December 31,
1998.
(8) Mr. Spoon resigned from his positions with the Company effective March
9, 1998.
(9) Dr. Collette resigned from his positions with the Company December 31,
1997.
PROPOSAL TO APPROVE AND ADOPT THE PLAN OF MERGER
AND ACQUISITION AGREEMENT DATED DECEMBER 18, 1998
BETWEEN THE COMPANY AND DEXTERITY
THE DESCRIPTION OF THE MERGER AND THE MERGER AGREEMENT SET FORTH BELOW
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE MERGER AGREEMENT, THE FULL TEXT
OF WHICH, AS AMENDED, IS CONTAINED IN APPENDIX A HERETO AND IS INCORPORATED
HEREIN BY REFERENCE.
DESCRIPTION OF THE MERGER
GENERAL
Upon consummation of the Merger, Dexterity will merge with and into
LifeQuest, and LifeQuest will be the Surviving Corporation. The Merger will be
effective after satisfaction (absent any waivers thereof) of all conditions
contained in the Merger Agreement, including the approval of the Merger by the
stockholders of LifeQuest. Each share of Common Stock outstanding before the
Merger will automatically be converted into a share of Common Stock following
the Merger.
After the Merger, approximately 10,200,000 shares of Common Stock of
LifeQuest will be outstanding, of which approximately 3,000,000 shares will be
held directly or indirectly by the former stockholders of Dexterity, other than
LifeQuest (the "Dexterity Stockholders"). Additionally, the Dexterity
Stockholders will, upon consummation of the Merger, hold warrants to purchase in
the aggregate an additional 1,500,000 shares of Common Stock of LifeQuest.
The Common Stock to be issued under the Merger Agreement, including the
Common Stock issuable pursuant to the Warrants, will be listed for trading on
the NASDAQ SmallCap Market. Life Quest has registered the class of Common Stock
with the Securities and Exchange Commission pursuant to Section 12 of the
Securities Exchange Act of 1934, as amended. LifeQuest's Certificate of
Incorporation does not provide for preemptive rights for its stockholders.
As consideration for the Merger, LifeQuest will pay to the Dexterity
Stockholders an aggregate of:
o $1,500,000;
o 3,000,000 shares of Common Stock;
o warrants to purchase an aggregate of 1,500,000 shares of
Common Stock (the "Warrants"), at an exercise price per share
of $2.00;
o promissory notes in the aggregate amount of $1,000,000 (the
"Promissory Notes"); and
o a royalty for seven years in an amount equal to 15% of all
sales of Dexterity products (the "Royalty") pursuant to a
royalty agreement (the "Royalty Agreement") among LifeQuest
and the Dexterity Stockholders. The Royalty is subject to
minimum annual payments which aggregate, over the seven years
of the Royalty Agreement, to approximately $1,500,000.
-5-
<PAGE> 9
BACKGROUND OF THE MERGER
In January 1998 the Company acquired approximately 20% of the common
stock, par value $1.00 ("Dexterity Stock"), of Dexterity for the purchase price
of $1,000,000. In connection with this investment, LifeQuest and Dexterity
entered into a distribution agreement whereby LifeQuest acquired the right to
distribute Dexterity's products within the United States. Approximately 65% of
Dexterity's revenues from its inception through September 30, 1998, are from
sales to LifeQuest. In November 1998 LifeQuest and Dexterity began negotiating
the terms of LifeQuest's acquisition of the remaining shares of Dexterity Stock
not already owned by LifeQuest. LifeQuest and Dexterity engaged in negotiations
until December 18, 1998, when LifeQuest and Dexterity executed the Merger
Agreement.
DEXTERITY
Dexterity is a medical device company incorporated by TeleFlex
Incorporated, a Delaware corporation ("TeleFlex") in the first quarter of 1998.
Prior to 1998, TeleFlex began research and development on technology which
evolved into Dexterity products. Prior it its incorporation, TeleFlex operated
Dexterity as a business unit through a subsidiary of TeleFlex.
Dexterity was created to advance the minimally invasive surgery ("MIS")
market through the development of disposable devices for hand assisted
laparoscopic surgery ("HALS"). The Dexterity product line includes the
Dexterity(R) Pneumo Sleeve and Dexterity(R) Protractor. Dexterity's address is
1787 Sentry Parkway West, Building Sixteen, Suite 220, Blue Bell, Pennsylvania
19422, and its telephone number is (215) 619-4241.
The Pneumo Sleeve is a device that allows the surgeon to insert one
hand into the abdominal cavity while preserving pneumopreperitoneum(1/) during
laparoscopic surgery. This new surgical modality, called HALS, is a hybrid
between open and laparoscopic surgery. This enabling technology is expected to
greatly increase the number of advanced minimal access surgeries as well as the
number of surgeons who perform these procedures. The U.S. market potential for
the Dexterity(R) Pneumo Sleeve is estimated at more than 580,000 procedures
annually, including digestive tract surgery, urinary tract surgery, organ
transplants, cancer surgery and vascular surgery. This translates into an
estimated $600 million U.S. market for Dexterity(R) procedural kits, which
include accessory devices such as hand-held surgical instruments.
In addition to being used with the Dexterity(R) Pneumo Sleeve, the
Dexterity(R) Protractor is used as a stand-alone product for open surgery,
providing atraumatic retraction and wound protection. The market potential for
the Dexterity(R) Protractor is estimated at 2.4 million surgical procedures per
year in the United States, representing a dollar market potential in excess of
$200 million.
The Company believes the potential exists for significant market
penetration by the Dexterity(R) products, and that sales of the Company's
existing product lines should benefit from these product introductions.
A number of prestigious medical centers in the United States are using
the Dexterity(R) Pneumo Sleeve and Protractor devices, including the University
of Massachusetts, the University of Texas at M.D. Anderson Cancer Center,
Vanderbilt University and the Advanced Laparoscopic Training Center. In
addition, the University of Michigan and the University of Wisconsin have
initiated clinical trials of HALS assisted nephrectomy(2/), and the Cleveland
Clinic Foundation has conducted various courses on HALS digestive surgery. The
Food and Drug Administration approved the Dexterity(R) Pneumo Sleeve and
Protractor for sale in the United States in July 1996. Since inception,
Dexterity has generated approximately $1,000,000 in sales revenue.
- --------
1/The presence of air or gas in the preperitoneal space; it may occur
spontaneously or be deliberately introduced as an aid to radiologic examination
and diagnosis.
2/The surgical removal of a kidney.
-6-
<PAGE> 10
LIFEQUEST'S REASONS FOR THE MERGER; RECOMMENDATION OF THE LIFEQUEST BOARD OF
DIRECTORS
At the meeting of the LifeQuest Board of Directors on December 8, 1998,
the LifeQuest Board approved the Merger and the Merger Agreement, and the other
agreements related to the Merger. In reaching its determination, the LifeQuest
Board considered the following material factors:
o The opportunity the Merger affords LifeQuest to increase its
presence in the MIS market, which should enable it to offer
its customers a broader and more varied array of products and
should also help to create an intellectual property portfolio
in the MIS products area;
o Dexterity is recognized as the pioneer and market leader in
the HALS products business, which LifeQuest believes has
significant earnings potential;
o The Merger is an opportunity for LifeQuest to expand into
higher margin manufacturing and distribution businesses;
o The expectation that the combined company would be better
positioned than LifeQuest on its own to benefit from
technological and other developments in the health care
industry in general and the MIS and HALS fields in
particular;
o The potential cost synergies offered by the Merger through
consolidation and integration of certain distribution, sales
and administrative operations and functions; and
o The absence of any significant business overlaps and
resulting absence of significant risks of objections from any
governmental authority.
The above discussion of the information and factors considered by the
LifeQuest Board is not exhaustive and does not include all factors considered by
the LifeQuest Board. In view of the variety of factors considered in connection
with its evaluation of the Merger, the LifeQuest Board did not find it
practicable to, and did not, quantify or otherwise assign relative weights to
the specific factors considered in reaching its determination. In addition,
individual members of the LifeQuest Board may have given different weights to
different factors. Based on the factors outlined above, the LifeQuest Board
determined that the Merger is in the best interests of LifeQuest and its
stockholders.
THE LIFEQUEST BOARD BELIEVES THAT THE MERGER IS IN THE BEST INTERESTS OF
LIFEQUEST AND ITS STOCKHOLDERS. THE LIFEQUEST BOARD, THEREFORE,
RECOMMENDS THAT ITS STOCKHOLDERS VOTE FOR APPROVAL OF THE MERGER
MATERIAL ADVANTAGES AND DISADVANTAGES OF THE MERGER
The LifeQuest Board has taken into account the advantages and
disadvantages of the proposed Merger to LifeQuest stockholders. Such advantages
are set forth above under the caption "Reasons for the Merger." Such
disadvantages include the dilution of voting power of current stockholders of
LifeQuest. After giving effect to the Merger, LifeQuest current stockholders
current voting power will be diluted by approximately 29%. In the event the
Dexterity Stockholders exercise the Warrants, the voting power of current
stockholders of LifeQuest will be diluted by 38%.
NAME CHANGE
Following approval by the stockholders of LifeQuest and contemporaneous
with the filing of the Certificate of Merger with the Secretary of State of the
State of Delaware, the Company will change its name to Dexterity Surgical, Inc.
-7-
<PAGE> 11
INTEREST OF CERTAIN PERSONS IN THE MERGER
After consummation of the Merger, the LifeQuest Board of Directors will
be comprised of ten (10) members: Richard A. Woodfield, Randall K. Boatright,
Robert Pearson, William H. Bookwalter, K C. Fadem, Robert L. Evans, Jeffrey H.
Berg, Robert B. Johnson, Christopher K. Black and Lewis Hatch. With the
exception of Messrs. Hatch and Black, each of such directors are currently
directors of LifeQuest. Mr. Hatch is currently a director of TeleFlex. TFX
Equities Incorporated, a Delaware corporation and wholly owned subsidiary of
TeleFlex ("TFX"), owns 57% of the outstanding Dexterity Stock. Mr. Black is
currently a director of Dexterity. Mr. Black owns 122 shares of Dexterity Common
Stock and has options to acquire an additional 80 shares of Dexterity Common
Stock. Pursuant to the terms of the Merger Agreement, Mr. Black will receive,
assuming he exercises his options, approximately $257,850, approximately 515,700
shares of Common Stock, a warrant to purchase 257,850 shares of Common Stock, a
promissory note made by the Company in the original principal amount of $171,970
and an undivided 17.19% interest in the Royalty to be paid pursuant to the
Royalty Agreement. In addition, Mr. Black will enter into a two year consulting
agreement with the Company, pursuant to which he will receive $40,000 per annum.
K.C. Fadem, a director and officer of LifeQuest, is a director and
officer, and owns 10.5% of the outstanding capital stock of Surgical Visions I,
Inc ("SVI"). Robert L. Evans, a director of LifeQuest, together with his wife,
owns 7% of the outstanding capital stock of SVI. SVI owns 165 shares, or 14% of
the outstanding shares of Dexterity Stock. K.C. Fadem and Robert L. Evans each
abstained from voting on the Merger and the Merger Agreement on all votes
related to the Merger by the Board of Directors of LifeQuest. Robert Fadem, an
officer of LifeQuest, owns 5.6% of SVI. In addition, eight other employees of
LifeQuest collectively own 10% of SVI. Pursuant to the terms of the Merger
Agreement, SVI will receive approximately $210,000, approximately 420,000 shares
of Common Stock, a warrant to purchase 210,000 shares of Common Stock, a
promissory note made by the Company in the original principal amount of $140,000
and an undivided 14% interest in the Royalty to be paid pursuant to the Royalty
Agreement.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unaudited condensed consolidated financial statements of each of
LifeQuest and Dexterity and pro forma condensed consolidated financial
statements of LifeQuest adjusted to reflect the effects of the Merger are
attached hereto and incorporated herein as Appendix B.
COMPARATIVE PER SHARE DATA
Comparative income (loss) per share data of LifeQuest and pro forma
comparative income (loss) per share data of LifeQuest adjusted to reflect the
effects of the Merger are included in the unaudited condensed consolidated
financial statements attached hereto and incorporated herein as Appendix B.
REGULATORY REQUIREMENTS
Under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the
"HSR Act"), certain acquisition transactions cannot be consummated unless
certain information has been furnished to the Federal Trade Commission ("FTC")
and the Antitrust Division of the United States Department of Justice
("Antitrust Division") and certain waiting period requirements have been
satisfied. In general, acquisitions in which the consideration paid is in excess
of $15,000,000, and the companies or persons involved are of a certain size,
require the providing of information regarding the acquisition on a PreMerger
Notification Form to the FTC and the Antitrust Division. Pursuant to the HSR
Act, an acquisition cannot be completed until at least 30 days after the parties
thereto have furnished the required information, unless the FTC and the
Antitrust Division terminate the waiting period earlier.
The Antitrust Division and the FTC frequently scrutinize the legality
under the antitrust laws of transactions such as the Merger. At any time before
or after the consummation of the Merger, the Antitrust Division or the FTC could
take any action under the antitrust laws that it deems necessary in the public
interest, including seeking to enjoin the consummation of the Merger. LifeQuest
does not believe the Merger will violate the antitrust laws.
As part of the consideration for the Merger to be paid by LifeQuest to
the Dexterity Stockholders is shares of Common Stock, the value of the
consideration, and whether a PreMerger Notification Form must be filed with the
FTC and the Antitrust Division, cannot be determined until the Merger is
effective. As of the date of this Proxy
-8-
<PAGE> 12
Statement, the Company is not required to file a PreMerger Notification Form
with the FTC or the Antitrust Division. However, should the market price of the
Common Stock increase between the date of this Proxy Statement and the
effectiveness of the Merger, a PreMerger Notification Form may need to be filed
the FTC and the Antitrust Division. It is possible, therefore, that the
necessary waiting periods may not expire until after the Special Meeting is held
and LifeQuest's stockholders vote on the Merger.
Other than as described in this Proxy Statement, the Merger does not
require the approval of any federal, state, or other agency.
ACCOUNTING TREATMENT
For accounting purposes, the Merger will be treated as a purchase with
LifeQuest being deemed to be the acquiring party and Dexterity being deemed to
be the acquired party.
CERTAIN FEDERAL INCOME TAX CONSEQUENCES
Neither LifeQuest nor its stockholders will recognize gain or loss for
U.S. federal income tax purposes as a result of the Merger. However, tax matters
are complicated, and the tax consequences of the Merger to you may change
depending on the facts of your own situation. We urge you to contact your own
tax advisor to understand fully how the Merger will affect you, including how
any State, local, or foreign tax laws may apply to you.
As of December 31, 1997, the Company had net operating loss ("NOL")
carryforwards of approximately $14,300,000 for federal income tax purposes that
are available to reduce future taxable income and will expire in 2006 through
2012 if not utilized.
The Company's ability to use its NOL carryforwards to offset future
taxable income is subject to restrictions enacted in the United States Internal
Revenue Code of 1986 as amended (the "Code"). These restrictions provide for
limitations on the Company's utilization of its NOL carryforwards following
certain ownership changes described in the Code. As a result of ownership
changes, the Company's existing NOL carryforwards are subject to limitation. As
a result of additional ownership changes resulting from the Merger, the
Company's ability to use its existing NOL carryforwards may be further limited.
Additionally, because United States tax laws limit the time during which NOL and
tax credit carryforwards may be applied against future taxable income and tax
liabilities, the Company may not be able to take full advantage of its NOL and
tax credits for federal income tax purposes.
DISSENTERS AND APPRAISAL RIGHTS
Pursuant to Section 262 of the Delaware General Corporation Law
("Section 262"), any LifeQuest stockholder who does not vote in favor of the
approval and adoption of the Merger Agreement (by voting against or abstaining)
and who has met the conditions, and properly complied with the requirements, of
Section 262 will be entitled to appraisal rights. The following summary of
Section 262 should be read in conjunction with, and is qualified in its entirety
by, the full text of Section 262, which is attached as Appendix C to this Proxy
Statement. By failing to follow the statutory procedures set forth in Section
262, a stockholder may terminate or waive such holder's appraisal rights.
Stockholders of record who wish to assert appraisal rights must (i)
hold their shares on the Record Date and on the date the merger becomes
effective and (ii) submit a written demand for such appraisal before the vote on
the Merger is taken. Such written demand must be in addition to and separate
from any proxy or vote against the Merger; and neither voting against,
abstaining from voting, nor failing to vote on the Merger will constitute a
demand for appraisal within the meaning of Section 262.
Within ten days after the date the Merger becomes effective, LifeQuest
will give written notice of the effectiveness of the Merger to all stockholders
of record who filed a written demand for appraisal and who did not vote in favor
of or consent to the Merger. Within 120 days after the date the Merger becomes
effective, any such stockholder, upon written request, shall have the right to
receive from LifeQuest a statement setting forth the aggregate number of shares
not voted in favor of the Merger and with respect to which demands for appraisal
have been received, and the aggregate number of holders of such shares.
-9-
<PAGE> 13
If LifeQuest and such stockholder do not agree upon the value of such
holder's shares of Common Stock, either LifeQuest or such holder may file within
120 days after the date the Merger becomes effective a petition in the Delaware
Court of Chancery demanding a determination of the value of such stockholder's
shares. In any such proceeding, the Court shall determine the fair market value
of the shares exclusive of any element of value arising from the accomplishment
or expectation of the Merger, together with a fair rate of interest, if any, to
be paid upon the fair value of the shares. The costs of the proceeding may be
determined by the Court and assessed against the parties as the Court deems
equitable in the circumstances. In addition, the Court may, upon application of
a stockholder, order all or any part of the expenses incurred by such holder in
connection with the appraisal proceeding, including, without limitation,
reasonable attorneys' fees and expenses and the fees and expenses of experts, to
be charged pro rata against the value of all the shares entitled to an
appraisal. Notwithstanding the foregoing, at any time within 60 days after the
date the Merger becomes effective, any such stockholder shall have the right to
withdraw such holder's demands for appraisal and to accept the terms offered in
the Merger. If no such petition for an appraisal is filed within 120 days of the
date the Merger becomes effective, then the right of such stockholder to
appraisal shall cease.
Any such stockholder who has demanded appraisal rights shall thereafter
neither be entitled to vote such holder's shares for any purpose nor be entitled
to the payment of dividends or other distributions on such shares (except any
dividends or other distributions payable to stockholders of record at a date
which is prior to the date the Merger becomes effective) unless such holder's
right to appraisal shall cease. If no petition for an appraisal shall be filed
within 120 days of the date the Merger becomes effective with the Delaware Court
of Chancery or if such holder delivers to LifeQuest a written withdrawal of such
holder's demand for an appraisal and an acceptance of the Merger, either within
60 days after the date the Merger becomes effective or thereafter with the
written approval of LifeQuest, then such holder's right to appraisal shall
cease.
Appraisal rights are exercisable only by the holder of record, not by a
beneficial owner who does not hold the shares of record.
THE MERGER AGREEMENT
EFFECTIVE TIME OF THE MERGER
As soon as practicable after satisfaction or waiver of the conditions
to consummation of the Merger, unless the Merger Agreement has been terminated
as provided therein, a certificate of merger (the "Certificate of Merger") will
be filed with the Secretary of State of the State of Delaware, at which time the
Merger will become effective (the "Effective Time"). It is presently
contemplated that the Effective Time will be as soon as practicable after
approval of the Merger at the Special Meeting and, in the event a PreMerger
Notification is required to be filed under the HSR Act, after the waiting
periods, if any, under the HSR Act.
TERMS OF THE MERGER AGREEMENT; RELATED AGREEMENTS
At the Effective Time, Dexterity shall be merged with and into
LifeQuest, with LifeQuest being the surviving corporation. From and after the
Effective Time, LifeQuest shall possess all assets and property, all interest in
assets or property, all rights and all debts belonging or due to each of
LifeQuest and Dexterity. In addition to issuing 3,000,000 shares of Common
Stock, the payment of $1,500,000, issuing the Warrants and the Promissory Notes
to the Dexterity Stockholders, LifeQuest shall also enter into the following
agreements:
1. The Royalty Agreement with the Dexterity Stockholders,
pursuant to which the Dexterity Stockholders will receive an
amount equal to either (i) the Royalty for the next seven (7)
years on all sales of Dexterity products sold by LifeQuest or
(ii) a minimum annual royalty which totals approximately
$1,500,000 over the seven year term of the Royalty Agreement;
2. A non-competition agreement (the "Non-Competition Agreement")
among LifeQuest, SVI, TFX , Christopher K. Black and TeleFlex
pursuant to which none of SVI, TFX, Christopher K. Black or
TeleFlex will, for a period of five (5) years, sell a device
that competes with the Dexterity(R) Pneumo Sleeve or
Protractor in either the United States or Canada;
-10-
<PAGE> 14
3. An indemnity agreement (the "Indemnity Agreement") among
LifeQuest, SVI, TFX and Christopher K. Black, pursuant to
which LifeQuest, on the one hand, and SVI, TFX and Christopher
K. Black, on the other hand, each agree to indemnify the other
for any damages arising out of a breach of any representation
and warranty or selected covenants of the Merger Agreement;
4. A consulting agreement (the "Consulting Agreement") with
Christopher K. Black, for a term of two (2) years, pursuant to
which LifeQuest shall pay Mr. Black $40,000 per annum for
various consulting services; and
5. A registration rights agreement (the "Registration Rights
Agreement") among LifeQuest and the Dexterity Stockholders
pursuant to which LifeQuest is obligated to register with the
Securities and Exchange Commission under the Securities Act of
1933, as amended (the "Securities Act"), the shares of Common
Stock issuable to the Dexterity Stockholders, including those
shares of Common Stock issuable pursuant to the Warrants,
pursuant to the Merger.
The Warrants grant the Dexterity Stockholders the right to purchase an
aggregate of 1,500,000 shares of Common Stock with an exercise price of $2 per
share. The Warrants expire ten (10) years from the day of grant and vest in
equal increments over five (5) years.
The Promissory Notes mature one year from the date they are made and
bear interest at 12% per annum.
CONDITIONS TO THE MERGER
The Merger Agreement provides that the respective obligations of
LifeQuest and Dexterity to effect the Merger are subject to the satisfaction or
waiver of various conditions: (a) that the Merger and the Merger Agreement shall
have been approved and adopted by the requisite vote of the stockholders of
LifeQuest as may be provided by law and any applicable provision of the
Certificate of Incorporation or Bylaws of LifeQuest; (b) no action, suit or
proceeding shall be pending or threatened before any court or quasi-judicial or
administrative agency of any federal, state, local or foreign jurisdiction or
before any arbitrator that would prevent or make illegal the consummation of the
Merger; (c) Christopher Black, SVI, TFX and TeleFlex shall have executed and
delivered to LifeQuest the Non-Competition Agreement and Indemnity Agreement;
(d) LifeQuest shall have executed and delivered to Christopher Black the
Consulting Agreement; (e) LifeQuest shall have executed and delivered to the
Dexterity Stockholders the Indemnity Agreement, the Registration Rights
Agreement and the Royalty Agreement; and (f) the representations and warranties
made by each of LifeQuest and Dexterity shall be true in all material respects.
REPRESENTATIONS AND WARRANTIES OF LIFEQUEST AND DEXTERITY
In the Merger Agreement, Dexterity and LifeQuest have made various
representations and warranties relating to, among other things, their respective
businesses and financial condition and the satisfaction of certain legal
requirements for the Merger. Dexterity has made various representations and
warranties relating to, among other things, certain litigation, employee benefit
and environmental matters and its ownership of certain intellectual properties.
EXCHANGE OF STOCK CERTIFICATES
On or before the Effective Time, LifeQuest will deliver to the
Dexterity Stockholders instructions for surrendering their certificates
representing shares of Dexterity Stock in exchange for certificates representing
Common Stock.
FEDERAL SECURITIES LAW CONSEQUENCES
Shares of Common Stock issued to the Dexterity Stockholders in
connection with the Merger will not be freely transferrable under the Securities
Act because such shares are being issued in a private placement pursuant to an
exemption from registration under Section 4(2) of the Securities Act. LifeQuest
has agreed to register pursuant to the Securities Act the shares of Common Stock
issuable to the Dexterity Stockholders pursuant to the Merger, including
-11-
<PAGE> 15
those shares issuable upon exercise of the Warrants. Until such shares are
registered under the Securities Act, they will be restricted under the
Securities Act.
MANNER AND BASIS OF CONVERTING SHARES
The Merger Agreement provides that at the Effective Time, the
outstanding shares of (i) Common Stock will remain as shares of Common Stock and
(ii) Dexterity Stock other than shares of Dexterity Stock held by LifeQuest,
which such shares will be cancelled, will be converted into the right to receive
an aggregate of:
o $1,500,000;
o 3,000,000 shares of Common Stock;
o the Warrants;
o the Promissory Notes; and
o the royalties under the Royalty Agreement.
As soon as is practicable following the Merger, LifeQuest will register
the issuance of Common Stock to the Dexterity Stockholders on the stock transfer
books of LifeQuest and exchange common stock certificates for the Dexterity
stock certificates.
No fractional shares of Common Stock will be issued in the Merger.
TERMINATION OR AMENDMENT OF MERGER AGREEMENT
The Merger Agreement may be terminated at any time prior to the
Effective Time by the mutual written consent of LifeQuest and Dexterity.
Dexterity may terminate the Merger Agreement if LifeQuest breaches any
representation, warranty or covenant contained in the Merger Agreement in any
material respect, and has not cured such breach within fifteen (15) days after
receipt of notice of the breach or if the Closing (as defined in the Merger
Agreement) does not occur before March 2, 1999. LifeQuest may terminate the
Merger Agreement if Dexterity breaches any representation, warranty or covenant
contained in the Merger Agreement in any material respect, and has not cured
such breach within fifteen (15) days after receipt of notice of the breach or if
the Closing (as defined in the Merger Agreement) does not occur before March 2,
1999. The Merger Agreement may be amended only pursuant to a written agreement
executed by each of LifeQuest and Dexterity.
VOTE AND RECOMMENDATION
The affirmative vote of the holders of a majority of all of the
outstanding shares of Common Stock and Preferred Stock of the Company is
required to approve and adopt the Merger and the terms of the Merger Agreement.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE PROPOSAL TO
APPROVE AND ADOPT THE MERGER AND THE TERMS OF THE MERGER AGREEMENT.
PROPOSALS FOR 1999 ANNUAL MEETING
The deadline for submission of stockholder proposals pursuant to Rule
14a-8 under the Securities Exchange Act of 1934, as amended ("Rule 14a-8"), for
inclusion in the Company's proxy statement for its 1999 annual meeting of
stockholders was December 13, 1998. After February 28, 1999, notice to the
Company of a stockholder proposal submitted otherwise than pursuant to Rule
14a-8 will be considered untimely, and the person named in proxies solicited by
the Board of Directors of the Company for its 1999 Annual Meeting of
Stockholders may exercise discretionary authority voting power with respect to
any such proposal as to which the Company does not receive timely notice.
-12-
<PAGE> 16
INCORPORATION OF CERTAIN DOCUMENTS
The Company's Annual Report on Form 10-KSB for the fiscal year ended
December 31, 1997, the Company's Quarterly Reports on Form 10-QSB for the
quarters ended March 31, June 30 and September 30, 1998, respectively, the
Company's Current Report on Form 8-K dated July 1, 1998 and the Company's
definitive Proxy Statement to its 1998 Annual Meeting of Stockholders held May
19, 1998 are hereby incorporated herein by reference.
All documents filed by the Company pursuant to Section 13(a), 13(c), 14
or 15(d) of the Exchange Act, after the date of this Prospectus and prior to the
termination of the Registration Statement of which this Prospectus is a part
with respect to registration of the Shares, shall be deemed to be incorporated
by reference in this Prospectus and be a part hereof from the date of filing of
such documents. Any statement contained in a document incorporated or deemed to
be incorporated by reference in this Prospectus shall be deemed to be modified
or superseded for purposes of this Prospectus to the extent that a statement
contained in this Prospectus, or in any other subsequently filed document which
also is or is deemed to be incorporated by reference, modifies or replaces such
statement.
The Company undertakes to provide without charge, within one business
day of the receipt of request, to each person to whom a copy of this Proxy
Statement has been delivered, upon written or oral request of any such person, a
copy of any or all of the documents incorporated by reference herein, other than
exhibits to such documents, unless such exhibits are specifically incorporated
by reference into the information that this Proxy Statement incorporates.
Written or oral requests for such copies should be directed to: LifeQuest
Medical, Inc., 12961 Park Central, Suite 1300, San Antonio, Texas 78216,
Attention: Randall K. Boatright, telephone (210) 495-8787.
OTHER MATTERS
As of the date of this Proxy Statement, management does not intend to
present any other items of business and is not aware of any matters to be
presented for action at the Special Meeting other than described above. However,
if any other matters should come before the Special Meeting, it is the intention
of the persons named as proxies in the accompanying proxy card to vote in
accordance with their best judgment on such matters.
By order of the Board of Directors,
RICHARD A. WOODFIELD
President and Chief Executive Officer
San Antonio, Texas
January _____, 1999
-13-
<PAGE> 17
APPENDIX A
PLAN OF MERGER AND ACQUISITION AGREEMENT
DATED EFFECTIVE DECEMBER 18, 1998
BETWEEN
LIFEQUEST MEDICAL, INC.
AND
DEXTERITY INCORPORATED
<PAGE> 18
<TABLE>
<CAPTION>
TABLE OF CONTENTS
<S> <C>
1. GENERAL DEFINITIONS......................................................................................1
1.1 "Accounts Receivable"...........................................................................1
1.2 "Affiliate".....................................................................................1
1.3 "Article".......................................................................................1
1.4 "Assets"........................................................................................1
1.5 "Authorization".................................................................................2
1.6 "Balance Sheet Date"............................................................................2
1.7 "Best Knowledge"................................................................................2
1.8 "Brokerage Fee".................................................................................2
1.9 "Business Combination"..........................................................................2
1.10 "Business Day"..................................................................................2
1.11 "CERCLA"........................................................................................2
1.12 "Certificate"...................................................................................2
1.13 "Closing".......................................................................................2
1.14 "Closing Date"..................................................................................2
1.15 "Code"..........................................................................................2
1.16 "Contracts".....................................................................................2
1.17 "Control".......................................................................................3
1.18 "Damages".......................................................................................3
1.19 "Deposits"......................................................................................3
1.20 "Effective Time"................................................................................3
1.21 "Encumbrance"...................................................................................3
1.22 "Environmental Laws"............................................................................3
1.23 "Exchange Act"..................................................................................3
1.24 "Financial Statements"..........................................................................3
1.25 "Governmental Authority"........................................................................3
1.26 "Governmental Requirement"......................................................................4
1.27 "Intellectual Property".........................................................................4
1.28 "LifeQuest Stock"...............................................................................4
1.29 "Merger"........................................................................................4
1.30 "Material Adverse Effect".......................................................................5
1.31 "Merger Consideration"..........................................................................5
1.32 "Parties "......................................................................................5
1.33 "Permitted Encumbrances"........................................................................5
1.34 "Person"........................................................................................5
1.35 "Reference Balance Sheet".......................................................................5
1.36 "Reorganization"................................................................................5
1.37 "Representations and Warranties of LifeQuest"...................................................5
1.38 "Representations and Warranties of Seller"......................................................5
1.39 "Royalty Agreement".............................................................................5
1.40 "Schedule"......................................................................................5
1.41 "SEC" or "Commission"...........................................................................5
1.42 "SEC Documents".................................................................................5
1.43 "Section".......................................................................................6
1.44 "Securities Act"................................................................................6
1.45 "Seller Stock"..................................................................................6
1.46 "Shareholders"..................................................................................6
1.47 "Subsidiary"....................................................................................6
1.48 "Surviving Corporation".........................................................................6
1.49 "Taxes".........................................................................................6
</TABLE>
-i-
<PAGE> 19
<TABLE>
<S> <C> <C>
1.50 "Tax Returns"...................................................................................6
1.51 "Teleflex"......................................................................................6
1.52 "Waste Materials"...............................................................................6
2. MERGER...................................................................................................6
2.1 The Merger......................................................................................6
2.2 Surviving Corporation...........................................................................7
2.3 Liabilities.....................................................................................7
2.4 Certificate of Incorporation and Bylaws.........................................................7
2.5 Directors and Officers..........................................................................7
2.6 Conversion or Cancellation of Stock Upon Merger.................................................7
2.7 Fractional Shares...............................................................................8
2.8 Exchange Procedures.............................................................................9
2.9 Interim Dividends...............................................................................9
2.10 Further Assurances..............................................................................9
3. CLOSING; CLOSING DATE....................................................................................9
4. REPRESENTATIONS AND WARRANTIES OF SELLER................................................................10
4.1 Incorporation..................................................................................10
4.2 Share Capital..................................................................................10
4.3 Financial Statements...........................................................................10
4.4 Events Since the Balance Sheet Date............................................................11
4.5 Taxes..........................................................................................11
4.6 Employee Matters...............................................................................12
4.7 Contracts and Agreements.......................................................................12
4.8 Effect of Agreement............................................................................14
4.9 Properties, Assets and Leasehold Estates.......................................................15
4.10 Intellectual Property..........................................................................15
4.11 Suits, Actions and Claims......................................................................15
4.12 Licenses and Permits; Compliance With Governmental Requirements................................16
4.13 Authorization..................................................................................16
4.14 Records........................................................................................16
4.15 Environmental Protection Laws..................................................................16
4.16 Accounts Receivable............................................................................17
4.17 Brokers and Finders............................................................................18
4.18 Deposits.......................................................................................18
4.19 Work Orders....................................................................................18
4.20 Customer List; Supplier List...................................................................18
4.21 No Royalties...................................................................................18
4.22 Bank Accounts..................................................................................18
4.23 Working Capital................................................................................18
4.24 Shareholder Approval...........................................................................19
4.25 No Untrue Statements...........................................................................19
5. REPRESENTATIONS AND WARRANTIES OF LIFEQUEST.............................................................19
5.1 LifeQuest Incorporation........................................................................19
5.2 Authorization..................................................................................19
5.3 Brokers and Finders............................................................................19
5.4 Authorization for Stock Consideration..........................................................19
5.5 SEC Documents..................................................................................19
6. NATURE OF STATEMENTS AND SURVIVAL OF REPRESENTATIONS AND WARRANTIES.....................................20
</TABLE>
-ii-
<PAGE> 20
<TABLE>
<S> <C>
7. TAX TREATMENT...........................................................................................20
8. PRE-CLOSING COVENANTS...................................................................................20
8.1 General........................................................................................20
8.2 Notices and Consents...........................................................................21
8.3 Operation of Business..........................................................................21
8.4 Full Access....................................................................................23
8.5 Notice of Developments.........................................................................23
8.6 Exclusivity....................................................................................23
9. CONDITIONS TO OBLIGATION TO CLOSE.......................................................................24
9.1 Conditions to Obligation of LifeQuest..........................................................24
9.2 Conditions to Obligation of Seller.............................................................25
10. SPECIAL CLOSING AND POST-CLOSING COVENANTS..............................................................26
10.1 General........................................................................................26
10.2 Litigation Support.............................................................................26
10.3 Transition.....................................................................................27
10.4 Intellectual Property Assignment...............................................................27
10.5 Tax-Free Reorganization........................................................................27
10.6 Teleflex Debt..................................................................................27
10.7 Board Representation...........................................................................27
11. NOTICES.................................................................................................27
12. TERMINATION.............................................................................................28
12.1 Termination of Agreement.......................................................................28
12.2 Effect of Termination..........................................................................29
13. GENERAL PROVISIONS......................................................................................29
13.1 Governing Law; Interpretation; Section Headings................................................29
13.2 Severability...................................................................................29
13.3 Entire Agreement...............................................................................30
13.4 Binding Effect.................................................................................30
13.5 Assignment.....................................................................................30
13.6 Amendment; Waiver..............................................................................30
13.7 Gender; Numbers................................................................................30
13.8 Counterparts...................................................................................30
13.9 Telecopy Execution and Delivery................................................................30
13.10 Expenses.......................................................................................31
13.11 Effect of Due Diligence........................................................................31
13.12 Press Releases and Public Announcements........................................................31
13.13 No Third Party Beneficiaries...................................................................31
13.14 Construction...................................................................................31
13.15 Incorporation of Exhibits, and Schedules.......................................................31
13.16 Specific Performance...........................................................................31
</TABLE>
-iii-
<PAGE> 21
<TABLE>
<CAPTION>
Exhibits
- --------
<S> <C>
1.20 Form of Certificate of Merger
2.6(a) Form of Warrant
2.6(b) Form of Promissory Note
2.6(c) Royalty Agreement
9.1(e)1 Form of Opinion of Seller's General Counsel
9.1(e)2 Form of Opinion of Seller's Intellectual Property Counsel
9.1(f) Form of Non-Competition Agreements
9.1(g) Form of Indemnity Agreement
9.2(e) Form of Consulting Agreement
9.2(g) Form of Registration Rights Agreement
9.2(i) Form of Opinion of LifeQuest's Counsel
10.4 Intellectual Property Assignment
Schedules
- ---------
4.2 Capitalization of Dexterity
4.3 Financial Statements
4.7 Material Contracts
4.8 Required Consents
4.9 Personal Property
4.10 Intellectual Property
4.11 Suits, Actions and Claims
4.12 Licenses and Permits
4.17 Brokers and Finders
4.20 Customers and Suppliers
4.21 Royalties
4.22 Bank Accounts
</TABLE>
-iv-
<PAGE> 22
PLAN OF MERGER AND ACQUISITION AGREEMENT
THIS PLAN OF MERGER AND ACQUISITION AGREEMENT (this "Agreement") is
made and entered into this 18th day of December 1998, between LifeQuest Medical,
Inc., a Delaware corporation ("LifeQuest") and Dexterity Incorporated, a
Delaware corporation ("Seller").
W I T N E S S E T H :
WHEREAS, LifeQuest is primarily in the business of distributing
minimally invasive surgical equipment and supplies; and
WHEREAS, Seller is in the business of distributing Dexterity(R)
products, including the pneumosleeve and protractor medical devices and surgical
instruments designed for use in handoscopic surgery (the "Business"); and
WHEREAS, the Shareholders own and hold all of the issued and
outstanding shares of capital stock of Seller not owned by LifeQuest; and
WHEREAS, the respective boards of directors of LifeQuest and Seller
have voted to approve the merger of Seller with and into LifeQuest (the
"Merger") pursuant to the terms and subject to the conditions of this Agreement;
and
WHEREAS, the transaction provided for in this Agreement is intended to
qualify as a corporate reorganization under Section 368 of the Internal Revenue
Code of 1986, as amended (the "Code");
NOW, THEREFORE, in consideration of the mutual covenants hereinafter
contained, the parties hereto agree that Seller shall be merged with and into
LifeQuest and that the terms and conditions of the Merger, the method of
carrying the Merger into effect and certain other provisions relating thereto
shall be as hereinafter set forth:
1. GENERAL DEFINITIONS. For purposes of this Agreement, the following
terms shall have the respective meanings set forth below:
1.1 "Accounts Receivable" shall have the meaning assigned to it in
Section 4.16.
1.2 "Affiliate" of any Person shall mean any Person Controlling,
Controlled by or under common Control with such Person.
1.3 "Article" shall mean an Article of this Agreement unless otherwise
stated.
1.4 "Assets" shall mean the assets, properties and rights of Seller of
every nature, kind and description, wherever located, tangible and intangible,
real, personal and mixed, whether or not
<PAGE> 23
reflected in the books and records of Seller necessary or desirable to permit
the Business to be carried on in the manner as is presently conducted.
1.5 "Authorization" shall mean any consent, approval or authorization
of, expiration or termination of any waiting period requirement (including
pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended) by, or filing, registration, qualification, declaration or designation
with, any Governmental Authority.
1.6 "Balance Sheet Date" shall have the meaning assigned to it in
Section 4.3.
1.7 "Best Knowledge" shall mean what a Person actually knew. When used
with respect to Seller, the term "Best Knowledge" shall mean Best Knowledge of
any of John J. Sickler, Christopher K. Black or Frederick C. Feiler.
1.8 "Brokerage Fee" shall mean the fee payable by Seller to Cleary &
Oxford Associates upon consummation of the transactions contemplated herein,
pursuant to the agreement referred to at Item 23 of Schedule 4.7.
1.9 "Business Combination" shall mean (i) any merger or consolidation
of, or share exchange involving, the Seller with or into any Person, (ii) any
sale, lease, exchange, transfer or other disposition (whether in one transaction
or a series of related transactions) or more than ten percent of the Seller's
consolidated assets (iii) the adoption of any plan or proposal for the
liquidation or dissolution of the Seller, (iv) any issuance, sale, purchase or
redemption of equity securities, any reclassification or equity securities of
recapitalization of the Seller, and (v) any transaction having an effect similar
to those described above.
1.10 "Business Day" shall mean any day other than Saturday, Sunday or
other day on which federally chartered commercial banks in San Antonio, Texas
are authorized or required by law to close.
1.11 "CERCLA" shall mean the Comprehensive Environmental, Response,
Compensation, and Liability Act of 1980, as amended.
1.12 "Certificate" shall mean each stock certificate representing
shares of Seller Stock.
1.13 "Closing" shall have the meaning assigned to it in Article 3.
1.14 "Closing Date" shall have the meaning assigned to it in Article 3.
1.15 "Code" shall mean the Internal Revenue Code of 1986, as amended.
1.16 "Contracts" shall have the meaning assigned to it in Section 4.7.
2
<PAGE> 24
1.17 "Control" and all derivations thereof shall mean the ability to
either (a) vote (or direct the vote of) 50% or more of the voting interests in
any Person or (b) direct the affairs of another, whether through voting power,
contract or otherwise.
1.18 "Damages" shall mean any and all liabilities, losses, damages,
demands, assessments, punitive damages, loss of profits, refund obligations
(including, without limitation, interest and penalties thereon) claims of any
and every kind whatsoever, costs and expenses (including interest, awards,
judgments, penalties, settlements, fines, costs of remediation, diminutions in
value, costs and expenses incurred in connection with investigating, prosecuting
and defending any claims or causes of action (including, without limitation,
reasonable attorneys' fees and reasonable expenses and all reasonable fees and
reasonable expenses of consultants and other professionals)).
1.19 "Deposits" shall have the meaning assigned to it in Section 4.18.
1.20 "Effective Time" shall mean the time at which a properly executed
certificate of merger in substantially the form attached to this Agreement as
Exhibit 1.20 (together with other documents required by law to effect the
Merger) shall have been filed with the Secretary of State of Delaware.
1.21 "Encumbrance" shall mean any security interest, mortgage, pledge,
trust, claim, lien, charge, option, defect, restriction, encumbrance or other
right or interest of any third Person of any nature whatsoever.
1.22 "Environmental Laws" shall mean any and all applicable laws,
statutes, ordinances, rules, regulations, orders, or determinations of any
Governmental Authority pertaining to the environment heretofore or currently in
effect in any and all jurisdictions in which Seller is conducting or at any time
has conducted business, or where any of the Assets are located, or where any
hazardous substances generated by or disposed of by Seller are located.
"Environmental Laws" shall include, but not be limited to, the Clean Air Act, as
amended, CERCLA, the Federal Water Pollution Control Act, as amended, RCRA, the
Safe Drinking Water Act, as amended, the Toxic Substances Control Act, as
amended, and all other applicable laws, statutes, ordinances, rules,
regulations, orders and determinations of any Governmental Authority relating to
(a) the control of any potential pollutant or protection of the air, water or
land, (b) solid, gaseous or liquid waste generation, handling, treatment,
storage, disposal or transportation and (c) exposure to hazardous, toxic or
other substances alleged to be harmful. The terms "hazardous substance,"
"release" and "threatened release" shall have the meanings specified in CERCLA,
and the terms "solid waste" and "disposal" (or "disposed") have the meanings
specified in RCRA.
1.23 "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.
1.24 "Financial Statements" shall have the meaning assigned to it in
Section 4.3.
1.25 "Governmental Authority" shall mean any and all foreign, federal,
state or local governments, governmental institutions, public authorities and
governmental entities of any nature whatsoever, and any subdivisions or
instrumentalities thereof, including, but not limited to,
3
<PAGE> 25
departments, boards, bureaus, commissions, agencies, courts, administrations and
panels, and any divisions or instrumentalities thereof, whether permanent or ad
hoc and whether now or hereafter constituted or existing.
1.26 "Governmental Requirement" shall mean any and all applicable laws
(including, but not limited to, applicable common law principles), statutes,
ordinances, codes, rules, regulations, interpretations, guidelines, directions,
orders, judgments, writs, injunctions, decrees, decisions or similar items or
pronouncements, promulgated, issued, passed or set forth by any Governmental
Authority in effect as of the Effective Time.
1.27 "Intellectual Property" shall mean:
(a) all of Seller's patents and applications therefor, further
including, but not limited to, all divisions, reissues, substitutions,
reexaminations, continuations, continuations-in-part and extensions thereof; and
(b) all of Seller's inventions, whether or not patentable,
further including, but not limited to, all new developments and inventions, as
well as all improvements on prior inventions regardless of prior inventorship;
and
(c) all of Seller's know-how and work product, regardless of
form and whether tangible or intangible, further including, but not limited to,
invention and laboratory notebooks, source code and object code, system design,
system specifications, flow charts, test data, records and journals; blueprints,
drawings and photographs; research and engineering reports, including any models
or other hardware; licensing, marketing or development analysis; and customer or
prospective customer lists; and
(d) all of Seller's copyright interests regardless of actual
or potential registrability, and including moral rights, rights of publication
and rights of attribution and integrity; and
(e) all of Seller's trademark or service mark interests,
together with all of the goodwill of the business associated therewith and
represented thereby; and
(f) all of Seller's trade secrets; and
(g) all of Seller's other intellectual property and other
proprietary interests, whether or not identifiable as of the date of execution
hereof, relating to, or used in connection with, the Business or Assets now or
at any time in the future.
1.28 "LifeQuest Stock" shall mean the common stock, $.001 par value, of
LifeQuest.
1.29 "Merger" shall have the meaning assigned to it in Section 2.1.
4
<PAGE> 26
1.30 "Material Adverse Effect" shall mean a material adverse effect on
the Business, Assets, properties, operations, condition (financial or otherwise)
or results of operations of Seller, or LifeQuest and its Subsidiaries taken as a
whole, as applicable.
1.31 "Merger Consideration" shall have the meaning assigned to it in
Section 2.6.
1.32 "Parties" or "parties" shall mean collectively LifeQuest and
Seller.
1.33 "Permitted Encumbrances" shall mean (a) Encumbrances for current
taxes and assessments not yet past due or which are being contested in good
faith by appropriate proceedings and with respect to which adequate reserves are
reflected in the Financial Statements, (b) mechanics and materialmen
Encumbrances for construction in progress to the extent not perfected by filing,
recording, giving of notice or other appropriate action in the relevant
jurisdiction, (c) workmen, repairmen, warehousemen, carriers, lessors and
operators Encumbrances arising in the ordinary course of business to the extent
not perfected by filing, recording, giving of notice or other appropriate action
in the relevant jurisdiction and (d) easements, including agreements and deeds
of easement, and other minor imperfections of title which would not have a
Material Adverse Effect.
1.34 "Person" shall mean any natural person, any Governmental Authority
and any entity, the separate existence of which is recognized by any
Governmental Authority or Governmental Requirement, including, but not limited
to, corporations, partnerships, joint ventures, joint stock companies, trusts,
estates, companies and associations, whether organized for profit or otherwise.
1.35 "Reference Balance Sheet" shall have the meaning assigned to it in
Section 4.3.
1.36 "Reorganization" shall have the meaning assigned to it in Article
7.
1.37 "Representations and Warranties of LifeQuest" shall have the
meaning assigned to it in Section 6.2.
1.38 "Representations and Warranties of Seller" shall have the meaning
assigned to it in Section 6.1.
1.39 "Royalty Agreement" shall mean the Royalty Agreement referred to
in the penultimate sentence of Section 2.6.
1.40 "Schedule" shall mean a Schedule to this Agreement unless
otherwise stated. The Schedules to this Agreement may be attached to this
Agreement or may be set forth in a separate document denoted as the Schedules to
this Agreement, or both.
1.41 "SEC" or "Commission" shall mean the United States Securities and
Exchange Commission.
1.42 "SEC Documents" shall have the meaning assigned to it in Section
5.5.
5
<PAGE> 27
1.43 "Section" shall mean a Section of this Agreement unless otherwise
stated.
1.44 "Securities Act" shall mean the Securities Act of 1933, as
amended.
1.45 "Seller Stock" shall mean the common stock, par value $1.00, of
Seller.
1.46 "Shareholders" shall mean the record owners, other that LifeQuest,
of the Seller Stock on the Closing Date.
1.47 "Subsidiary" shall mean, with respect to any Person (the
"parent"), (a) any corporation, association, joint venture, partnership or other
business entity of which securities or other ownership interests representing
more than 50% of the ordinary voting power or beneficial interest are, at the
time as of which any determination is being made, owned or controlled by the
parent or one or more subsidiaries of the parent or by the parent and one or
more subsidiaries of the parent and (b) any joint venture or partnership of
which the parent or any Subsidiary of the parent is a general partner or has
responsibility for its management.
1.48 "Surviving Corporation" shall mean the corporation existing at and
after the Effective Time as a result of the Merger.
1.49 "Taxes" shall mean any foreign, federal, state or local tax,
assessment, levy, impost, duty, withholding, estimated payment or other similar
governmental charge, together with any penalties, additions to tax, fines,
interest and similar charges thereon or related thereto.
1.50 "Tax Returns" shall mean all Tax returns and reports (including,
without limitation, income, franchise, sales and use, unemployment compensation,
excise, severance, property, gross receipts, profits, payroll and withholding
Tax returns and information returns).
1.51 "Teleflex" means Teleflex Incorporated, a Delaware corporation.
1.52 "Waste Materials" shall mean any toxic or hazardous materials or
substances, or solid wastes, including asbestos, buried contaminants, chemicals,
flammable or explosive materials, radioactive materials, petroleum and petroleum
products, and any other chemical, pollutant, contaminant, substance or waste
that is regulated by any Governmental Authority under any Environmental Law.
2. MERGER.
2.1 The Merger. Subject to the terms and conditions of this Agreement,
Seller shall be merged with and into LifeQuest in accordance with all applicable
laws (the "Merger"), with LifeQuest being the Surviving Corporation. LifeQuest
and Seller shall cause a certificate of merger to be filed with the Secretary of
State of Delaware on the Closing Date (as hereinafter defined). The Merger shall
be effective at the Effective Time.
6
<PAGE> 28
2.2 Surviving Corporation. From and after the Effective Time, the
Surviving Corporation shall have the name "Dexerity Surgical, Inc." and shall
possess all assets and property of every description, and every interest in the
assets and property, wherever located, and the rights, privileges, immunities,
powers, franchises and authority, of a public as well as of a private nature, of
each of Seller and LifeQuest, and all debts and all other things in action or
belonging or due to each of Seller and LifeQuest, all of which shall be vested
in the Surviving Corporation without further act or deed, and title to any real
estate or any interest in the real estate vested in either Seller or LifeQuest
shall not revert or in any way be impaired.
2.3 Liabilities. The Surviving Corporation shall be liable for all the
debts, liabilities and duties of each of Seller and LifeQuest; any action or
proceeding pending, by or against either Seller or LifeQuest, may be prosecuted
to judgment, with right of appeal, as if the Merger had not taken place, or the
Surviving Corporation may be substituted in its place, and all the rights of
creditors of each of Seller and LifeQuest shall be preserved unimpaired, and all
liens upon the property of each of Seller and LifeQuest shall be preserved
unimpaired, on only the property affected by the liens immediately prior to the
Effective Time.
2.4 Certificate of Incorporation and Bylaws. The certificate of
incorporation and bylaws of LifeQuest in effect immediately prior to the
Effective Time shall be the certificate of incorporation and bylaws of the
Surviving Corporation following the Merger until otherwise amended or repealed.
2.5 Directors and Officers. Subject to the provisions of Section 10.7
hereof, the directors and officers of LifeQuest immediately prior to the
Effective Time shall be the directors and officers of the Surviving Corporation
until their successors are duly elected or appointed and qualified in the manner
provided in the bylaws of the Surviving Corporation, or as otherwise provided by
law.
2.6 Conversion or Cancellation of Stock Upon Merger. In consideration
for the Merger and the non-competition agreements and indemnity agreements
described in Section 9.1 hereof, as of the Effective Time, by virtue of the
Merger and without any action on the part of the holders of any shares of Seller
Stock, or the holder of the shares of LifeQuest Stock:
(a) each share of Seller Stock outstanding immediately before the
Effective Time and held by the Shareholders shall be converted into the
right to receive, subject to Section 2.7,
(i) the numbers of shares of LifeQuest Stock equal to the
quotient of (1) 3,000,000 divided by (2) the number
of shares of Seller Stock held by the Shareholders
immediately before the Effective Time (the "Stock
Consideration");
(ii) the quotient of (1) $1,500,000, less 50% of Brokerage
Fee divided by (2) the number of shares of Seller
Stock held by the Shareholders immediately before the
Effective Time (the "Cash Consideration");
(iii) a warrant dated the Closing Date substantially in the
form attached hereto as Exhibit 2.6(a) to purchase
such number of shares of LifeQuest Stock equal to
7
<PAGE> 29
the quotient of (1) 1,500,000 divided by (2) the
number of shares of Seller Stock held by the
Shareholders immediately before the Effective Time,
all at an exercise price of $2.00 per share (the
"Warrants");
(iv) a promissory note dated the Closing Date
substantially in the form attached hereto as Exhibit
2.6(b) in a principal amount equal to the quotient of
(1) $1,000,000 divided by (2) the number of shares of
Seller Stock held by the Shareholders immediately
before the Effective Time, payable within one year
from the date of Closing and accruing interest at the
rate of 12% per annum (the "Promissory Notes" and,
together with Stock Consideration, the Cash
Consideration and the Warrants, the "Merger
Consideration"); and
(v) an undivided fractional interest in the Royalty
Agreement equal to one over the number of shares of
Seller Stock held by the Shareholders immediately
before the Effective Time.
(b) each share of Seller Stock outstanding immediately before the
Effective Time and held by LifeQuest shall be converted into the right
to receive one (1) share of common stock of the Surviving Corporation;
and
(c) each share of LifeQuest Stock outstanding immediately before the
Effective Time shall be converted into one share of Common Stock of the
Surviving Corporation.
At the Closing, LifeQuest shall (i) issue and deliver to the Shareholders
certificates representing the Stock Consideration, (ii) pay the Cash
Consideration, (iii) issue and deliver the Warrants and the Promissory Notes to
the Shareholders, (iv) execute and deliver to TFX Equities, as agent for the
Shareholders, a Royalty Agreement, dated the Closing Date, in substantially the
form of Exhibit 2.6(c) and (v) execute and deliver to the proper Persons an
assumption of the assignment of those contracts and agreements of Seller listed
on Schedule 4.7 which require an express assumption of the liabilities of Seller
as contained in such contracts or agreements. At the Closing, Seller shall
execute and deliver to LifeQuest the intellectual property assignment as
contemplated by Section 10.4.
2.7 Fractional Shares. Notwithstanding Section 2.6, no certificates or
scrip representing fractional shares of LifeQuest Stock shall be issued upon the
surrender for exchange of certificates that prior to the Effective Time
represented shares of Seller Stock, no dividend or distribution of LifeQuest
shall relate to any fractional share interest and no fractional share interest
shall entitle the owner thereof to vote or to exercise any rights of a
stockholder of LifeQuest. In the event that any Former Seller Shareholder shall
be entitled to any fractional share interest then any fractional amount shall be
rounded down to the nearest whole share.
8
<PAGE> 30
2.8 Exchange Procedures.
(a) After the Effective Time, each outstanding Certificate
shall, until duly surrendered to LifeQuest as contemplated by this Section 2.8,
be deemed to represent only the right to receive the Merger Consideration.
(b) After the Effective Time, there shall be no further
transfer on the records of Seller of Certificates, and each share of Seller
Stock presented or surrendered to LifeQuest shall be canceled in exchange for
the Merger Consideration as contemplated by Section 2.6. LifeQuest shall not be
obligated to deliver Merger Consideration to any holder of a Certificate until
such holder surrenders such Certificate as provided herein.
2.9 Interim Dividends. No dividends or other distributions declared
after the Effective Time on LifeQuest Stock issuable pursuant to the Merger and
payable to a Former Seller Shareholder after the Effective Time shall be paid to
the holder of any unsurrendered certificates formerly representing shares of
Seller Stock until the certificates shall be surrendered as provided herein,
provided, however, that (a) upon surrender there shall be paid to the
shareholder in whose name the certificates representing the shares of LifeQuest
Stock shall be issued the amount of unpaid dividends with respect to the
holder's shares of LifeQuest Stock and (b) at the appropriate payment date, or
as soon as practicable thereafter, there shall be paid to the shareholder the
amount of dividends declared with respect to whole shares of LifeQuest Stock
with a record date on or after the Effective Time but before surrender and a
payment date subsequent to surrender, subject in any case to any applicable
escheat laws. No interest shall be payable with respect to the payment of
dividends or other distributions on surrender of outstanding certificates.
2.10 Further Assurances. If at any time after the Effective Time the
Surviving Corporation shall consider or be advised that any further assignments
or assurances in law or otherwise are necessary or desirable to vest, perfect or
confirm, of record or otherwise, in the Surviving Corporation, all rights, title
and interests in all the Assets and all privileges, powers and franchises of
Seller, the Surviving Corporation and its proper officers and directors, in the
name and on behalf of Seller, shall execute and deliver all such proper deeds,
assignments and assurances in law and do all things necessary and proper to
vest, perfect or confirm title to such property or rights in the Surviving
Corporation and otherwise to carry out the purpose of this Agreement, and the
proper officers and directors of the Surviving Corporation are fully authorized
in the name of Seller or otherwise to take any and all such action.
3. CLOSING; CLOSING DATE.
As soon as practicable after satisfaction or waiver of all conditions
to the Merger, including the approval by the stockholders of LifeQuest of the
Merger and the issuance of the Stock Consideration, the consummation of the
transactions referenced above shall take place (the "Closing") at 10:00 a.m.,
E.S.T., at the offices of Saul, Ewing, Remick & Saul, LLP, Centre Square West,
1500 Market Street, 38th Floor, Philadelphia, Pennsylvania or at such other
time, date and place as LifeQuest and Seller shall in writing designate. The
date of the Closing is referred to herein as the "Closing Date".
9
<PAGE> 31
4. REPRESENTATIONS AND WARRANTIES OF SELLER. Seller hereby represents
and warrants to the LifeQuest as follows:
4.1 Incorporation. Seller is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware, and is
qualified and in good standing as a foreign corporation in Pennsylvania. Seller
is not required to qualify or otherwise be authorized to do business as a
foreign corporation in any other jurisdiction in order to carry on any of its
businesses as now conducted or to own, lease or operate the Assets except for
such jurisdictions where the failure to so qualify will not have a Material
Adverse Effect. Complete and correct copies of the Certificate of Incorporation
of Seller and all amendments thereto, certified in each case by the Secretary of
State of the State of Delaware, and of the Bylaws of Seller and all amendments
thereto, certified by the Secretary of Seller, heretofore have been delivered to
LifeQuest. The minute books of Seller previously made available to LifeQuest are
complete and accurately reflect all action taken prior to the date of this
Agreement by its board of directors and shareholders, in their capacities as
such. Seller has no Subsidiaries. Seller is not engaged in any business or
operations other than the Business.
4.2 Share Capital
(a) The authorized capital stock of Seller consists of 4,000
shares of Seller Stock, of which 1,263 shares are outstanding as of the date
hereof, and 1,000 shares of preferred stock of Seller, of which none shares are
outstanding as of the date hereof. All of the outstanding Seller Stock is held
of record by the Persons identified as such owners on Schedule 4.2. All
outstanding Seller Stock is duly authorized and issued in compliance with all
federal, state and foreign securities laws. True and correct copies of the stock
records of Seller, showing all issuances and transfers of shares of capital
stock of Seller since inception, have previously been provided to LifeQuest.
(b) On the Closing Date there will be outstanding no rights of
first refusal, preemptive rights, conversion rights, options, warrants or other
rights to acquire, directly or indirectly, capital stock from Seller. Set forth
in Schedule 4.2 is the number of options outstanding on the date hereof, the
grant dates and exercise prices thereof (in each case, as applicable).
(c) Seller is not a party or subject to any agreement or
understanding, and to the Best Knowledge of Seller there is no agreement or
understanding between any Persons, that affects or relates to the voting or
giving of written consents with respect to any securities of Seller or the
voting by any director of Seller. No Shareholder nor any Affiliate thereof is
indebted to Seller. Seller is not indebted to any Shareholder or any Affiliate
thereof other than Teleflex Incorporated ("Teleflex").
4.3 Financial Statements. Seller has delivered to LifeQuest copies of
the following financial statements for Seller, all of which financial statements
are included in Schedule 4.3 (collectively, the "Financial Statements"):
Unaudited Balance Sheet of Seller (the "Reference Balance Sheet") as of October
31, 1998 (the "Balance Sheet Date") and Unaudited Income Statement of Seller for
the ten-month period ended on the Balance Sheet Date. The Financial Statements
have been prepared in accordance with generally accepted accounting principles
applied on a consistent
10
<PAGE> 32
basis throughout the periods indicated, and present fairly the financial
condition of Seller as of the dates and for the periods indicated thereon,
except that such financial statements do not include footnote disclosures which
are required by generally accepted accounting principles. However, all material
matters which would have been disclosed in such footnotes are disclosed in this
Agreement and the Schedules hereto or in the documents referred to in this
Agreement or such Schedules.
4.4 Events Since the Balance Sheet Date. Since the Balance Sheet Date,
there has not been:
(a) any change in the condition (financial or otherwise) or in
the properties, assets, liabilities, business or prospects of the Business,
except changes in the ordinary course of business, all of which in the aggregate
have not been materially adverse; (b) any breach or default by Seller or, to the
Best Knowledge of Seller, by any other party, under any agreement or obligation
included in the Assets or by which any of the Assets are bound; (c) any damage,
destruction or loss (whether or not covered by insurance) materially adversely
affecting the Assets or the Business; (d) any material change in the types,
nature, composition or quality of the services of the Business, any material
adverse change in the contributions of any of the service lines of the Business
to the revenues or net income of such Business, or any adverse change in the
sales, revenue or net income of the Business; (e) any transaction related to or
affecting the Assets or the Business other than transactions in the ordinary
course of business of Seller; (f) any declaration, setting aside or payment of
any dividend (whether in cash, stock or property) with respect to any of
Seller's capital stock except as permitted by Section 8.3; (g) (i) any granting
by Seller to any executive officer of Seller of any increase in compensation
payable after the Closing Date, (ii) any granting by Seller to any executive
officer of any increase in severance or termination pay payable after the
Closing Date, or (iii) any entry by Seller into any employment, severance or
termination agreement with any executive officer; (h) any change in accounting
methods, principles or practices by Seller materially affecting its assets,
liabilities or business, except insofar as may have been required by a change in
tax-basis or generally accepted accounting principles, and except as required by
LifeQuest; (i) any condition, event or occurrence through the date hereof which,
in the aggregate, could reasonably be expected to prevent, hinder or delay in
any material respect the ability of Seller to consummate the transactions
contemplated by this Agreement; or (j) any agreement, in writing or otherwise,
by Seller or any corporate action by Seller with respect to the foregoing.
4.5 Taxes.
(a) All Tax Returns of or relating to any Taxes that are
required to be filed on or before the Effective Time, subject to any allowable
extension periods, for, by, on behalf of or with respect to Seller, including,
but not limited to, those relating to the income, business, operations or
property of Seller (whether on a separate, consolidated, affiliated, combined,
unitary or any other basis), have been or will prior to the Effective Time be
timely filed with the appropriate foreign, federal, state and local authorities,
and all Taxes shown to be due and payable on such Tax Returns have been or will
prior to the Effective Time be paid in full on or before the Effective Time,
except Taxes which have not yet become due, before the Effective Time, liability
for which is or will prior to the Effective Time be reflected on the Seller's
books of account;
11
<PAGE> 33
(b) all Taxes assessed and due and owing from or against
Seller on or before the Effective Time have been or will be timely paid in full
on or before the Effective Time; and
(c) all withholding Tax, Tax deposit and estimated Tax payment
requirements imposed on Seller for any and all periods ending on or before the
Effective Time, or through and including the Effective Time for periods that
have not ended on or before the Effective Time, have been or will be satisfied
in full on or before the Effective Time or reserves adequate for the payment of
such withholding, deposit and estimated Taxes have been or will be established
in the books of account of Seller on or before the Effective Time.
4.6 Employee Matters. Seller has no employees and has not at any time
in the past had any employees.
4.7 Contracts and Agreements. (a) Except for the contracts or
arrangements referred to in Schedule 4.7, Seller is not a party to or bound by:
(i) any contract, agreement or commitment in respect of the
sale or distribution of products or services or the purchase of raw materials,
supplies or other products or utilities other than pending orders given or
received in the ordinary course of business consistent with past practice;
(ii) any offer, tender or the like outstanding and capable of
being converted into an obligation of Seller by the passage of time or by an
acceptance or other act of some other person or entity or both, except for those
incurred in the ordinary course of Seller's business, none of which have had a
Material Adverse Effect;
(iii) any sale, agency, distributorship agreement, franchise
agreement or legally enforceable commitment or obligation with respect thereto;
(iv) any collective bargaining agreement, union agreement,
employment agreement, consulting agreement, management service agreement,
agreement providing for the services of an independent contractor or any other
similar type of contract or agreement;
(v) any profit-sharing, pension, stock option, severance pay,
retirement, bonus, deferred compensation, group life and health insurance or
other employee benefit plan, agreement, arrangement or commitment of a similar
nature or any agreement with any present or former officer, director or
shareholder of Seller;
(vi) any loan or credit agreement, indenture, guarantee (other
than endorsements made for collection), mortgage, pledge, conditional sale or
other title retention agreement, any equipment financing obligation, lease and
lease-purchase agreement;
(vii) any lease related to the Assets or the Business, and any
other contract, agreement or legally enforceable commitment relating to or
affecting the Assets or the Business;
12
<PAGE> 34
(viii) any performance bond, bid bond, surety bond and the
like, any contract and bid covered by such bond, and any letter of credit and
guaranty;
(ix) any consent decree and other judgment, decree or order,
settlement agreement and agreement relating to competitive activities, requiring
or prohibiting any future action;
(x) any contract, commitment or agreement of any nature with a
Shareholder, or Affiliate of a Shareholder;
(xi) any contracts, commitments and agreements entered into
outside the ordinary course of the operation of the Business;
(xii) any agreement, indenture or other instrument which
contains restrictions with respect to the payment of dividends or any other
distribution in respect of its capital stock or the purchase, redemption or
other acquisition of capital stock;
(xiii) other than expenditures regularly made in the ordinary
course of business of Seller for items that are not property, plant or
equipment, any agreement, contract or commitment relating to any expenditure or
a series of related expenditures in excess of $10,000;
(xiv) any outstanding loan or advance by Seller to, or
investment by Seller in, any Person, or any agreement, contract, commitment or
understanding relating to the making of any such loan, advance or investment
(excluding trade receivables);
(xv) any contract, agreement, indenture, note or other
instrument relating to (A) the borrowing of money by Seller or the granting of
any Encumbrance or (B) any guarantee or other contingent liability (identifying
the primary contract or agreement to which such guarantee or contingent
liability relates or the agreement pursuant to which such guarantee was
delivered) in respect of any indebtedness, commitment, liability or obligation
of any Person (other than the endorsement of negotiable instruments for deposit
or collection in the ordinary course of business);
(xvi) any agreement, contract or commitment limiting the
freedom of Seller or any Affiliate of Seller to engage in any line of business,
to own, operate, sell, transfer, pledge or otherwise dispose of or encumber any
Asset or to compete with any Person or to engage in any business or activity in
any geographic area;
(xvii) any agreement, lease, contract or commitment or series
of related agreements, leases, contracts or commitments not entered into in the
ordinary course of business that is not cancelable under the terms of such
agreement, lease, contract or commitment without penalty to Seller within 30
days;
(xviii) any agreement, contract or commitment requiring (A)
the payment for goods or services whether or not such goods or services are
actually provided or (B) the furnishing of goods or services at a price less
than Seller's cost of producing such goods or providing such services;
13
<PAGE> 35
(xix) any agreement or contract obligating Seller or that
would obligate or require any subsequent owner of the business currently
conducted by Seller or any of the Assets to provide for indemnification or
contribution with respect to any matter (other than customary indemnification
provisions in leases of property leased by Seller);
(xx) any license, royalty or similar agreement; or
(xxi) any agreement, contract or commitment that Seller
expects to have a Material Adverse Effect on Seller and/or LifeQuest subsequent
to Closing.
(b) All of such contracts, agreements, leases, licenses,
plans, arrangements, commitments and documents specified in Schedule 4.7
(collectively, the "Contracts") are to the Best Knowledge of Seller valid,
binding and in full force and effect. To the Best Knowledge of Seller there are
no facts or documents rendering any Contract unenforceable by Seller or
otherwise invalid. There is no existing default thereunder or breach thereof by
Seller, or, to the Best Knowledge of Seller, by any other party to a Contract,
or any conditions which, with the passage of time or the giving of notice or
both, would constitute such a default by Seller, or, to the Best Knowledge of
Seller, by any other party to a Contract, and none of the Contracts will be
breached by or give any other party a right of termination as a result of the
transactions contemplated by this Agreement. There are no pending or, to the
Best Knowledge of Seller, threatened disputes with respect to the Contracts.
There are no obligations, including payment of money, past due by either party
to any Contract. There are no disclosed or undisclosed breaches of warranty,
whether or not within a time period to cure, pertaining to any Contract. There
is no condition existing that has or will trigger a right to terminate any
Contract. There is no requirement in any Contract requiring a third party to be
a signatory to this Agreement. Copies of all of the Contracts (or in the case of
oral commitments, descriptions of the material terms thereof) have been
delivered by Seller to LifeQuest, and such copies and/or descriptions are true,
complete and accurate and include all amendments, supplements or modifications
thereto. All of the contracts are assignable to and assumable by LifeQuest as
set forth herein so as to give LifeQuest exactly the same rights and/or
obligations thereunder enjoyed by Seller, without the requirement of obtaining
any consent or approval, giving any prior or subsequent notice, paying any
further royalty or fee to any party thereto or to any other third party, or
performing any duty that has not already been fully performed by Seller. All of
the Contracts will be fully vested in LifeQuest as of the Effective Time of the
Merger, without the approval or consent of any Person.
4.8 Effect of Agreement. The execution and delivery of this Agreement
and the consummation of the transactions contemplated hereby will not (a)
violate any provision of the Articles of Incorporation or other charter
documents or bylaws of Seller; (b) result in any violation of any Governmental
Requirement applicable to Seller, the Assets or the Business; (c) conflict with,
or result in any breach of, or default or loss of any right under (or an event
or circumstance that, with notice or the lapse of time, or both, would result in
a default), or the creation of an Encumbrance pursuant to, or cause or permit
the acceleration prior to maturity or "put" right with respect to, any
obligation under, any contract, indenture, mortgage, deed of trust, lease, loan
agreement or other agreement or instrument to which Seller is a party or to
which any of the Assets or Business are subject; or (d) require notice to or the
consent, authorization, approval, clearance, waiver or order of any Person
(except as specified in Schedule 4.8). The execution, delivery and performance
of this
14
<PAGE> 36
Agreement by Seller will not result in the loss of any governmental license,
franchise or permit possessed by Seller.
4.9 Properties, Assets and Leasehold Estates.
(a) Set forth on Schedule 4.9 is a description of each item of
personal property, excluding inventory, owned by Seller that had a book value as
of the Balance Sheet Date greater than $10,000. For purposes of this Section
4.9, "personal property" excludes Intellectual Property. Seller owns all of such
personal property free and clear of all Encumbrances, except for Permitted
Encumbrances and those Encumbrances set forth on Schedule 4.9.
(b) Seller leases no personal property.
(c) Seller owns no real property.
(d) Seller leases no real property.
4.10 Intellectual Property.
(a) Schedule 4.10 is a complete list of Intellectual Property
in which Seller either has an ownership interest or rights/obligations pursuant
to agreements.
(b) Except as set forth in agreements itemized on, or
otherwise disclosed in, Schedule 4.10, (i) there is no contract obligation of
Seller concerning, or any license or encumbrance affecting Seller's interest in
or title to, such Intellectual Property; (ii) Seller has received no notice that
the manufacture or sale by Seller of any of the products offered for sale by
Seller infringes the patent or trademark rights of any other Person nor, to the
Best Knowledge of Seller, is there any valid basis for any such claim; and (iii)
to the Best Knowledge of Seller no product presently offered for sale by any
Person infringes the patent rights of Seller. To the Best Knowledge of Seller,
Seller's use of the Intellectual Property does not infringe on any third party
proprietary interest, including (without limitation) any third party patent,
copyright, trademark, or trade secret interest. To the Best Knowledge of Seller,
Seller's right to the exclusive use of the Intellectual Property is not being
infringed by any third party proprietary interest, including (without
limitation) any third party patent, copyright, trademark, or trade secret
interest. To the Best Knowledge of Seller, except for agreements itemized on
Schedule 4.10, no agreements or arrangements are in effect with respect to the
development, nondisclosure, marketing, distribution, licensing, or promotion of
the Intellectual Property by any independent contractor, salesperson,
distributor, sublicensor, or other remarketer or sales organization.
4.11 Suits, Actions and Claims. Except as set forth in Schedule 4.11,
(a) there are no suits, actions, claims, or to the Best Knowledge of Seller,
investigations by any Person, or any legal, administrative or arbitration
proceedings in which Seller is engaged, which are pending or, to the Best
Knowledge of Seller, threatened, against or affecting Seller or any of its
properties, assets or business, or to which Seller is or might become a party,
or which question the validity or legality of the transactions contemplated
hereby, (b) to the Best Knowledge of Seller, no reasonable basis or
15
<PAGE> 37
reasonable grounds for any such suit, action, claim, investigation or proceeding
exists, and (c) there is no outstanding order, writ, injunction or decree of any
Governmental Authority against or affecting Seller or any of its properties,
assets or business.
4.12 Licenses and Permits; Compliance With Governmental Requirements.
No federal, state, local or foreign governmental license or permit is necessary
for the conduct by Seller of the operation of its business as currently
conducted, except for the licenses, permits and approvals required to be
obtained by Medical Creative Technologies, Inc. referred to in Schedule 4.12.
Seller has not received and is not aware of any reports of inspections under the
United States Occupational Safety and Health Act, or under any other applicable
federal, state or local health and safety laws and regulations relating to
Seller, the Assets or the operation of Seller's business. There are no safety,
health, anti-competitive or discrimination claims that have been made or are
pending or, to the Best Knowledge of Seller, that are threatened relating to the
business or employment practices of Seller. Seller has complied with all
Governmental Requirements applicable to its business and all Governmental
Requirements with respect to the distribution and sale of products and services
by it.
4.13 Authorization. Seller has full legal right, power, and authority
to enter into and deliver this Agreement, to consummate the transactions set
forth herein and to perform all the terms and conditions hereof to be performed
by it. The execution and delivery of this Agreement by Seller and the
performance by it of the transactions contemplated herein have been duly and
validly authorized by all requisite corporate actions of Seller, and this
Agreement has been duly and validly executed and delivered by Seller and is the
legal, valid and binding obligation of Seller, enforceable against Seller in
accordance with the terms of the Agreement, except as limited by applicable
bankruptcy, moratorium, insolvency or other similar laws affecting generally the
rights of creditors or by principles of equity.
4.14 Records. The books, records and minutes kept by Seller with
respect to the Assets and the Business, including, but not limited to, all
customer files, service agreements, correspondence and historic revenue of
Seller, have been kept properly and contain records of all matters required to
be included therein by any Governmental Requirement or by generally accepted
accounting principles, and such books, records and minutes are true, accurate
and complete in all material respects.
4.15 Environmental Protection Laws.
(a) Seller has at all times operated in compliance with all
applicable limitations, restrictions, conditions, standards, prohibitions,
requirements and obligations of Environmental Laws and related orders of any
court or other Governmental Authority.
(b) There are no existing, pending or, to the Best Knowledge
of Seller, threatened actions, suits, claims, investigations or proceedings by
or before any court or any other Governmental Authority directed against Seller
or its Assets or the Business which pertain or relate to (i) any remedial
obligations under any applicable Environmental Law, (ii) violations of any
Environmental Law, (iii) personal injury or property damage claims relating to
the release of chemicals or Waste Materials or (iv) response, removal or
remedial costs under CERCLA or any similar state law.
16
<PAGE> 38
(c) All notices, permits, licenses or similar authorizations
required to be obtained or filed by Seller under all applicable Environmental
Laws in connection with its current and previous operation or use of the Assets,
any other assets or properties currently or previously leased or owned by Seller
or the current and previous conduct of its business have been duly obtained or
filed and are in full force and effect.
(d) Seller has not received notice that any permit, license or
similar authorization referred to in subparagraph (a) above, is to be revoked or
suspended by any Governmental Authority.
(e) Seller does not own or operate any underground storage
tanks.
(f) No portion of the Assets or any other assets or properties
currently or previously leased or owned by Seller is part of a Superfund site
under CERCLA or any similar ranking or listing under any similar state law.
(g) All Waste Materials generated by Seller have been
transported, stored, treated and disposed of by carriers, storage, treatment and
disposal facilities authorized and maintaining valid permits under all
applicable Environmental Laws.
(h) No Person has disposed or released any Waste Materials on
or under the Assets or any other asset or property currently or previously
leased or owned by Seller and Seller has not disposed or released Waste
Materials on or under the Assets or any other asset or property currently or
previously leased or owned by Seller, except in compliance with all
Environmental Laws.
(i) No facts or circumstances exist which could reasonably be
expected to result in any liability of Seller to any Person with respect to the
current or past business and operations of Seller, the Assets or any other
assets or properties currently or previously leased or owned by Seller in
connection with (i) any release, transportation or disposal of any Waste
Materials, hazardous substance or solid waste or (ii) action taken or omitted
that was not in full compliance with or was in violation of, any applicable
Environmental Law.
4.16 Accounts Receivable. All notes and accounts receivable of Seller
that are reflected on the Reference Balance Sheet or that have arisen since the
Balance Sheet Date ("Accounts Receivable") have arisen in the ordinary course of
business. All Accounts Receivable either (a) have been collected or (b) are
collectible on the respective due dates thereof, or, if no due date is stated
with respect thereto, within 150 days of their creation in the ordinary course
of business, in each case in the aggregate recorded amounts thereof, less the
applicable reserves with respect thereto reflected on the Reference Balance
Sheet. Seller has not factored or discounted or agreed to factor or discount any
Account Receivable. The values at which the Accounts Receivable are carried on
the Reference Balance Sheet reflect the accounts receivable valuation policy of
Seller which is consistent with Seller's past practice and in accordance with
generally accepted accounting principles consistently applied. No Accounts
Receivable have been written off by Seller, in whole or in part, as
uncollectible during the two years preceding the date hereof.
17
<PAGE> 39
4.17 Brokers and Finders. Except as set forth in Schedule 4.17, no
broker or finder has acted for Seller or, to the Best Knowledge of Seller, any
Shareholder in connection with this Agreement or the transactions contemplated
by this Agreement and no broker or finder is entitled to any brokerage or
finder's fee or to any commission in respect thereof based in any way on
agreements, arrangements or understandings made by or on behalf of Seller or
any, to the Best Knowledge of Seller, Shareholder.
4.18 Deposits. Seller does not now hold any deposits or prepayments
(except prepayments for goods ordered in the aggregate not exceeding $10,000) by
third parties with respect to any of the Assets or the Business ("Deposits").
4.19 Work Orders. There are no outstanding work orders or contracts
relating to any portion of the Assets from or required by any policy of
insurance, fire department, sanitation department, health authority or other
Governmental Authority nor is there any matter under discussion with any such
parties or authorities relating to work orders or contracts.
4.20 Customer List; Supplier List.
(a) Schedule 4.20 sets forth a true, correct and complete list of all
customers of the Business to which Seller has sold or provided products or
services since inception. This list provides an accurate statement of the gross
revenues received from each such customer by the Business during the ten-month
period ended October 31, 1998.
(b) Schedule 4.20 sets forth a true, correct and complete list of all
suppliers of the Business from which Seller has purchased or otherwise received
more than $10,000 worth of products or services since inception. This list
provides an accurate statement of the gross payments to each such supplier by
the Business during the ten-month period ended October 31, 1998.
4.21 No Royalties. Except as set forth on Schedule 4.21, no royalty or
similar item or amount is being paid or is owing by Seller, nor is any such item
accruing, with respect to the operation, ownership or use of the Business or the
Assets.
4.22 Bank Accounts. Schedule 4.22 sets forth a true and complete list
of all bank or financial accounts and safe deposit boxes of Seller and of the
credit and debit balances of such bank and financial accounts as of the most
recent practicable date. Except as set forth in Schedule 4.22, since the date of
the balances set forth on such list, there have been no payments out of or
drafts against any of the accounts included therein other than routine payments
and drafts in the ordinary course of business, and the balances in such accounts
as of the date hereof are not materially different from those reflected in such
list. Schedule 4.22 also lists all persons having signatory authority over or
access to such bank and financial accounts and safe deposit boxes.
4.23 Working Capital. On the Closing Date, the current assets of Seller
will exceed the current liabilities of Seller, as determined in accordance with
generally accepted accounting principles.
18
<PAGE> 40
4.24 Shareholder Approval. This Agreement and transactions contemplated
herein have been approved by the Shareholders of Seller, and such approval
cannot be revoked unless this Agreement is terminated pursuant to provisions of
Article 12 hereof.
4.25 No Untrue Statements. The Representations and Warranties of Seller
set forth in this Agreement do not include any untrue statement of a material
fact or omit to state any material fact necessary to make such Representations
and Warranties made not misleading.
5. REPRESENTATIONS AND WARRANTIES OF LIFEQUEST. LifeQuest represents
and warrants to Seller as follows:
5.1 LifeQuest Incorporation. LifeQuest is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware.
5.2 Authorization. LifeQuest has have full legal right, power and
authority, corporate and otherwise, to enter into this Agreement and to
consummate the transactions set forth herein and to perform all the terms and
conditions hereof to be performed by them. The execution and delivery of this
Agreement and the performance by LifeQuest of the transactions contemplated
herein have been duly authorized by all requisite corporate action of LifeQuest
and is the legal, valid and binding obligation of LifeQuest, enforceable against
LifeQuest in accordance with its terms, except as limited by applicable
bankruptcy, moratorium, insolvency or similar laws affecting generally the
rights of creditors or by principles of equity.
5.3 Brokers and Finders. No broker or finder has acted for LifeQuest in
connection with this Agreement or the transactions contemplated by this
Agreement and no broker or finder is entitled to any brokerage or finder's fee
or to any commission in respect thereof based in any way on agreements,
arrangements or understandings made by or on behalf of LifeQuest.
5.4 Authorization for Stock Consideration. LifeQuest has taken all
necessary action to permit it to issue the number of shares of Stock
Consideration required to be issued pursuant to the terms of this Agreement. The
shares of Stock Consideration issued pursuant to the terms of this Agreement
will, when issued, be validly issued, fully paid and nonassessable and not
subject to preemptive rights. The Stock Consideration issuable pursuant to this
Agreement will, when issued, be listed on the NASDAQ SmallCap Market.
5.5 SEC Documents. LifeQuest has provided to Seller and each
Shareholder its Form S-3 dated October 30, 1998, its Annual Report on Form
10-KSB/A for the year ended December 31, 1997, its Quarterly Reports on Form
10-QSB for the quarters ended March 31, 1998, June 30, 1998, and September 30,
1998 and its proxy statement with respect to the Annual Meeting of Stockholders
held on May 19, 1998 (such documents collectively referred to herein as the "SEC
Documents"). As of their respective dates, the SEC Documents complied in all
material respects with the requirements of the Exchange Act and the rules and
regulations of the Commission promulgated thereunder applicable to such SEC
Documents, and none of the SEC Documents contained any untrue statement of a
material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in light of the
circumstances under which they were
19
<PAGE> 41
made, not misleading. The consolidated financial statements of LifeQuest
included in the SEC Documents comply as to form in all material respects with
applicable accounting requirements and the published rules and regulations of
the Commission with respect thereto, have been prepared in accordance with
generally accepted accounting principles applied on a consistent basis during
the periods involved (except as may be indicated in the notes thereto) and
fairly present the consolidated financial position of LifeQuest and its
consolidated Subsidiaries as of the dates thereof and the consolidated results
of their operations and cash flows for the periods then ended (except in the
case of interim period financial information for normal year-end adjustments).
6. NATURE OF STATEMENTS AND SURVIVAL OF REPRESENTATIONS AND WARRANTIES.
6.1 "Representations and Warranties of Seller" means all of
the representations and warranties of Seller set forth in Article 4, including
the statements in the Schedules referred to in Article 4, and the statements of
Seller set forth in the certificate delivered by Seller at Closing pursuant to
Section 9.1(d). All Representations and Warranties of Seller shall survive the
Effective Time regardless of any investigation at any time made by or on behalf
of LifeQuest. The covenants and agreements made by Seller herein, shall continue
until all obligations with respect thereto shall have been performed or
satisfied or shall have been terminated in accordance with their respective
terms.
6.2 "Representations and Warranties of LifeQuest" means all of
the representations and warranties of LifeQuest set forth in Article 5,
including the statements of LifeQuest set forth in the certificate delivered by
LifeQuest at Closing pursuant to Section 9.2(d). All Representations and
Warranties of LifeQuest shall survive the Effective Time regardless of any
investigation at any time made by or on behalf of Seller. The covenants and
agreements made by LifeQuest herein, shall continue until all obligations with
respect thereto shall have been performed or satisfied or shall have been
terminated in accordance with their respective terms.
7. TAX TREATMENT.
Seller and LifeQuest intend that the transactions contemplated
hereunder constitute a tax-free reorganization (a "Reorganization") for federal
income tax purposes under Sections 368(a)(1) and 368(a)(2)(D) of the Code, and
agree to treat and report for federal income tax purposes the transactions
hereunder as a Reorganization. This Agreement shall be construed in a manner to
result in treatment of the transactions hereunder as a Reorganization for
federal income tax purposes.
8. PRE-CLOSING COVENANTS.
The Parties agree as follows with respect to the period between the
execution of this Agreement and the Closing:
8.1 General. Each of the Parties will use his or its best
efforts to take all action and to do all things necessary, proper, or advisable
in order to consummate and make
20
<PAGE> 42
effective the transactions contemplated by this Agreement (including
satisfaction, but not waiver, of the closing conditions set forth in
Article 9).
8.2 Notices and Consents. Each of the Parties, as promptly as
practicable, (i) will make, or cause to be made, all filings and
submissions required under laws, rules and regulations applicable to
it, or to its Subsidiaries and Affiliates, as may be required for it to
consummate the transactions contemplated hereby; (ii) will use their
best efforts to obtain, or cause to be obtained, all authorizations,
approvals, consents and waivers from all Persons and Governmental
Authorities necessary to be obtained by each of them, or any of their
respective Subsidiaries or Affiliates, in order for each of them,
respectively, so to consummate such transactions; and (iii) will use
their respective best efforts to take, or cause to be taken, all other
actions necessary, proper or advisable in order for each of them to
fulfill their respective obligations hereunder.
8.3 Operation of Business. Except as contemplated by this
Agreement or as set forth in the Schedules, during the period from the
date of this Agreement to the Effective Time, (a) Seller will conduct
its operations according to its ordinary course of business and
consistent with past practice, (b) Seller will not enter into any
transaction other than in the ordinary course of business and
consistent with past practice, (c) Seller will deliver to LifeQuest on
or before the 15th day of each month true and correct unaudited monthly
balance sheets and statements of income for the Business for the
immediately preceding month, and (d) to the extent consistent with the
foregoing, using best efforts and with no less diligence and effort
than would be applied in the absence of this Agreement, Seller will
seek to preserve intact its current business organizations, keep
available the services of its current officers and consultants and
preserve its relationships with customers, suppliers and others having
business dealings with it with the objective that their goodwill and
ongoing businesses shall be unimpaired at the Effective Time; provided
that nothing in this Agreement shall be deemed to limit the right of
Seller to declare and pay dividends in cash to its shareholders
(including the declaration of dividends to its shareholders payable
after the Effective Time) so long as no such declaration or payment
shall result in a breach of the warranty set forth in Section 4.23. For
purposes of this Agreement any such permitted declaration of cash
dividends payable after the Effective Time shall be treated as a
liability of Seller which shall be assumed by the Surviving Corporation
pursuant to Article 2. Without limiting the generality of the
foregoing, and except as otherwise permitted in this Agreement, prior
to the Effective Time, Seller will not, without the prior written
consent of LifeQuest:
(a) except for Seller Stock issued upon exercise of options
outstanding as of the date hereof, issue, deliver, sell, dispose of,
pledge or otherwise encumber, or authorize or propose the issuance,
delivery, sale, disposition or pledge or other Encumbrance of (i) any
additional shares of its capital stock of any class (including the
Seller Stock), or any securities or rights convertible into,
exchangeable for or evidencing the right to subscribe for any shares of
its capital stock, or any rights, warrants, options, calls, commitments
or any other agreements of any character to purchase or acquire any
shares of its capital stock or any securities or rights convertible
into, exchangeable for or evidencing the right to subscribe for
21
<PAGE> 43
any shares of its capital stock, or (ii) any other securities in
respect of, in lieu of or in substitution for Seller Stock outstanding
on the date hereof;
(b) redeem, purchase or otherwise acquire, or propose to
redeem, purchase or otherwise acquire, any of its outstanding
securities (including the Seller Stock);
(c) (i) grant any increases in the compensation of any of its
directors, officers or key employees, (ii) pay or agree to pay any
pension, retirement allowance or other employee benefit hereof to any
such director, officer or key employee, whether past or present, (iii)
enter into any new, or amend any existing, employment agreement with
any such director, officer or key employee, (iv) enter into any new, or
amend any existing, severance agreement with any such director, officer
or key employee, or (v) except as may be required to comply with
applicable law, amend any existing, or become obligated under any new
employee benefit plan;
(d) adopt a plan of complete or partial liquidation,
dissolution, merger, consolidation, restructuring, recapitalization or
other reorganization of Seller (other than the Merger);
(e) make any acquisition, by means of merger, consolidation or
otherwise, of (i) any direct or indirect ownership interest in or
assets comprising any business enterprise or operation or (ii) any
other assets in excess of $10,000;
(f) adopt any amendments to its Certificate of Incorporation
or Bylaws;
(g) incur any long-term indebtedness for borrowed money or
guarantee any such indebtedness or make any loans, advances or capital
contributions to, or investments in, any other Person;
(h) amend any Contract;
(i) enter into or amend or assume any mortgage, pledge,
conditional sale or other title retention agreement, lien, encumbrance
or charge of any kind upon any of the Assets, or selling, leasing,
abandoning or otherwise disposing of any of the Assets, including, but
not limited to, real property, machinery, equipment or other operating
properties;
(j) increasing the compensation of any officer or employee of
Seller associated with the Business;
(k) engage in the conduct of any business the nature of which
is different then the business Seller is currently engaged in;
(l) enter into or assume any oral or written agreement
providing for acceleration of payment or performance or other
consequence as a result of a change of control of Seller or its
Subsidiaries;
22
<PAGE> 44
(m) except for purchases of inventory pursuant to existing
contracts or arrangements, enter into or assume any oral or written
contract, arrangement or understanding requiring the purchase of
equipment, materials, supplies or services for the expenditure of
greater than $10,000;
(n) incur any liabilities other than in the ordinary course of
business;
(o) hire any employee; or
(p) authorize or announce an intention to do any of the
foregoing, or enter into any contract, agreement, commitment or
arrangement to do any of the foregoing.
8.4 Full Access. Seller will, and cause each Shareholder to,
permit representatives of LifeQuest and its financing parties to have
full access at all reasonable times, and in a manner so as not to
interfere with the normal business operations of the Seller to all
premises, properties, personnel, books, records (including Tax records
and the workpapers of the independent accountants for the Seller),
contracts and documents of or pertaining to the Seller .
8.5 Notice of Developments. Each Party will give prompt
written notice to the others of any material adverse development which
has caused a breach of any of its own representations and warranties in
Articles 4 or 5 above and not been cured within five days and Seller
will give proper notice to LifeQuest of any development which has
caused a breach of its covenants contained in Section 8.3 above and not
cured within five days. No disclosure by any Party pursuant to this
Section 8.5, however, shall be deemed to amend or supplement the
Schedules hereto or to prevent or cure any misrepresentation, breach of
warranty or breach of covenant.
8.6 Exclusivity.
(a) Unless and until this Agreement has been terminated
pursuant to Section 12.1, Seller will not, and will not cause or permit
any of the Shareholders to, (i) solicit, initiate or encourage the
submission of any proposal or offer from any Person relating to a
Business Combination or (ii) participate in any discussions or
negotiations regarding, furnish any information with respect to, assist
or participate in, or facilitate in any other manner any effort or
attempt by any Person to do or seek a Business Combination. Seller
will, and cause each Shareholder with such knowledge to, notify
LifeQuest immediately if any Person makes any proposal, offer, inquiry,
or contact with respect to any of the foregoing.
(b) The Parties hereto recognize and acknowledge that a breach
by Seller of this Section 8.6 will cause irreparable and material loss
and damage to LifeQuest as to which it will not have an adequate remedy
at law or in damages. Accordingly, each Party acknowledges and agrees
that the issuance of an injunction or other equitable remedy is an
appropriate remedy for any such breach. In addition, in the event of
any breach of the foregoing which results in Business Combination with
a Person other than LifeQuest, Seller
23
<PAGE> 45
shall be liable for and promptly reimburse LifeQuest for the reasonable
expenses incurred by LifeQuest in connection with the transactions
contemplated by this Agreement.
9. CONDITIONS TO OBLIGATION TO CLOSE
9.1 Conditions to Obligation of LifeQuest. The obligation of
LifeQuest to consummate the transactions to be performed by it in
connection with the Closing is subject to satisfaction of the following
conditions:
(a) All Seller's Representations and Warranties
contained in this Agreement (except for the Representations
and Warranties contained in Sections 4.10(b) and 4.11 to the
extent that such Representations and Warranties relate to
claims, demands or notices, or knowledge acquired after the
date of this Agreement) all written information delivered to
LifeQuest by Seller on or prior to the Closing Date pursuant
to this Agreement, (i) that are qualified as to materiality
shall be true in all respects on and as of the Closing Date
and (ii) that are not qualified as to materiality shall be
true in all material respects on and as of the Closing Date
with the same force and affect as though such representations
and warranties were made, and such written information was
delivered, on and as of the Closing Date;
(b) Seller shall have performed and complied with all
of its covenants hereunder in all material respects through
the Closing;
(c) no action, suit or proceeding shall be pending or
threatened before any court or quasi-judicial or
administrative agency of any federal, state, local, or foreign
jurisdiction or before any arbitrator wherein an unfavorable
injunction, judgment, order, decree, ruling or charge would
(i) prevent consummation of any of the transactions
contemplated by this Agreement, (ii) cause any of the
transactions contemplated by this Agreement to be rescinded
following consummation, (iii) affect adversely the right of
LifeQuest to control the Seller, (iv) affect adversely the
right of the Seller to own its assets and to operate its
businesses, or (v) require or could reasonably be expected to
require any divestiture by the Seller of a portion of its
business that LifeQuest in its reasonable judgment believes
will have a material adverse effect on the Seller (and no such
injunction, judgment, order, decree, ruling or charge shall be
in effect);
(d) Seller shall have delivered to LifeQuest a
certificate to the effect that each of the conditions
specified above in Section 9.1(a), (b) and (c) is satisfied in
all respects;
(e) LifeQuest shall have received from counsel to
Seller opinions in substantially in the form attached hereto
as Exhibits 9.1(e)(1) and 9.1(e)(2), addressed to LifeQuest,
and dated as of the Closing Date;
24
<PAGE> 46
(f) Christopher K. Black, Surgical Visions I, Inc.,
TFX Equities, Inc. and Teleflex shall have executed and
delivered Non-Competition Agreements in the form of Exhibit
9.1(f) hereto;
(g) Christopher K. Black, TFX Equities Incorporated,
Teleflex and Surgical Visions I, Inc. shall have executed and
delivered Indemnity Agreements in the form of Exhibit 9.1(g)
hereto;
(h) The oral agreements between Seller and Teleflex
listed as items 11 and 12 on Schedule 4.7 hereto shall have
been terminated; and
(i) The stockholders of LifeQuest shall have approved
this Agreement and the consummation by LifeQuest of the
transactions contemplated hereby, including but not limited to
the issuance of the Stock Consideration.
LifeQuest may waive any condition specified in this Section 9.1 if it
executes a writing so stating at or prior to the Closing.
9.2 Conditions to Obligation of Seller. The obligation of
Seller to consummate the transactions to be performed by it in
connection with the Closing is subject to satisfaction of the following
conditions:
(a) all Representations and Warranties of LifeQuest
contained in this Agreement, and all written information
delivered to Seller by LifeQuest on or prior to the Closing
Date pursuant to this Agreement, (i) that are qualified as to
materiality shall be true in all respects on and as of the
Closing Date and (ii) that are not qualified as to materiality
shall be true in all material respects on and as of the
Closing Date, with the same force and effect as though such
representations and warranties were made, and such written
information was delivered, on and as of the Closing Date;
(b) LifeQuest shall have performed and complied with
all of its covenants hereunder in all material respects
through the Closing;
(c) no action, suit, or proceeding shall be pending
or threatened before any court or quasi-judicial or
administrative agency of any federal, state, local or foreign
jurisdiction or before any arbitrator wherein an unfavorable
injunction, judgment, order, decree, ruling or charge would
(A) prevent consummation of any of the transactions
contemplated by this Agreement or (B) cause any of the
transactions contemplated by this Agreement to be rescinded
following consummation (and no such injunction, judgment,
order, decree, ruling or charge shall be in effect);
(d) LifeQuest shall have delivered to Seller a
certificate to the effect that each of the conditions
specified above in Section 9.2(a), (b) and (c) is satisfied in
all respects;
25
<PAGE> 47
(e) LifeQuest shall have executed and delivered a
Consulting Agreement between LifeQuest and Christopher K.
Black in the form of Exhibit 9.2(e) hereto; and
(f) LifeQuest shall have executed and delivered the
Indemnity Agreement in the form of Exhibit 9.1(g) attached
hereto;
(g) LifeQuest shall have executed and delivered the
Registration Rights Agreement in the form attached hereto as
Exhibit 9.2(g);
(h) LifeQuest shall have executed and delivered the
Royalty Agreement with TFX Equities Incorporated as agent for
the Shareholders in the form attached hereto as Exhibit
2.6(c);
(i) Seller and the Shareholders shall have received
from counsel to LifeQuest an opinion substantially in the form
attached hereto as Exhibit 9.2(i) addressed to Seller, and
dated as of the Closing Date; and
(j) all actions to be taken by LifeQuest in
connection with consummation of the transactions contemplated
hereby and all certificates, opinions, instruments and other
documents required to effect the transactions contemplated
hereby will be reasonably satisfactory in form and substance
to Seller.
Seller may waive any condition specified in this Section 9.2 if it
executes a writing so stating at or prior to the Closing.
10. SPECIAL CLOSING AND POST-CLOSING COVENANTS.
The Parties agree as follows with respect to the period following the Closing:
10.1 General. In case at any time after the Closing any further action
is necessary or desirable to carry out the purposes of this Agreement, each of
the Parties will take such further action (including the execution and delivery
of such further instruments and documents) as any other Party reasonably may
request, all at the sole cost and expense of the requesting Party (unless the
requesting Party is entitled to indemnification therefor pursuant to the terms
of the Indemnity Agreement. Seller acknowledges and agrees that from and after
the Closing LifeQuest will be entitled to possession of all documents, books,
records (including Tax records), agreements, and financial data of any sort
relating to the Seller.
10.2 Litigation Support. In the event and for so long as any Party or
Teleflex or any of its Affiliates actively is contesting or defending against
any action, suit, proceeding, hearing, investigation, charge, complaint, claim
or demand in connection with (i) any transaction contemplated under this
Agreement or (ii) any fact, situation, circumstance, status, condition,
activity, practice, plan, occurrence, event, incident, action, failure to act or
transaction on or prior to the Closing Date involving the Seller, Seller will
cooperate with LifeQuest and its counsel in the contest or defense, make
available their personnel, and provide such testimony and access to their books
and records as
26
<PAGE> 48
shall be necessary in connection with the contest or defense, all at the sole
cost and expense of the contesting or defending Party (unless the contesting or
defending Party is entitled to indemnification therefor pursuant to the terms of
the Indemnity Agreement.
10.3 Transition. Seller will not take any action that is designed or
intended to have the effect of discouraging any lessor, licensor, customer,
supplier or other business associate of the Seller from maintaining the same
business relationships with the Surviving Corporation after the Closing as it
maintained with the Seller prior to the Closing.
10.4 Intellectual Property Assignment. Although acknowledged by all
parties as also fully enabled by the Merger memorialized by this Agreement,
Seller shall also execute a separate assignment to LifeQuest of all of Seller's
right, title and interest in and to the Intellectual Property. This separate
assignment shall be in form reasonably satisfactory to Seller and LifeQuest, and
recordation thereof shall be at the sole discretion of LifeQuest.
10.5 Tax-Free Reorganization. Seller shall not, nor permit any
Shareholder to, nor shall LifeQuest, take any action which would disqualify the
transactions contemplated by this Agreement from treatment as a tax-free
reorganization of the Seller, to the extent that such treatment is otherwise
available to the Shareholders.
10.6 Teleflex Debt. Promptly following the Effective Time, LifeQuest
shall pay all amounts due from Seller to Teleflex.
10.7 Board Representation. At or prior to the Closing, LifeQuest's
Board of Directors shall elect Christopher K. Black and Lewis E. Hatch, Jr. to
serve as directors of LifeQuest effective as of the Effective Time. LifeQuest
shall take all requisite action to amend its Bylaws, if necessary, to increase
the size of its Board of Directors in order to effect the appointments
contemplated by this Section 10.7. For so long as Teleflex and its Affiliates
together shall hold in the aggregate more than 50% of the aggregate number of
shares of LifeQuest Stock acquired by Teleflex and its Affiliates pursuant
hereto, LifeQuest will cause each of two persons nominated by Teleflex and
acceptable to LifeQuest's Board of Directors to be nominated for election of
directors at LifeQuest's annual meetings of stockholders.
10.8 Exchange Act Filing; Cooperation. After the Closing Date, Seller
shall, and cause its Affiliates to, reasonably cooperate with and provide
information to LifeQuest as is necessary for LifeQuest to comply with its
reporting obligations under the Exchange Act, including, but not limited to, all
financial and other information, which shall include audited balance sheets,
income statements and statements of cash flow for two years prior to Closing,
and access to Seller's affiliates' personnel required in order for Seller to
comply with its reporting obligations under the Exchange Act.
11. NOTICES. All notices, requests, demands and other communications
required or permitted to be given hereunder shall be in writing and shall be
deemed to have been duly given if delivered personally, given by prepaid telex
or telegram or by facsimile or other similar instantaneous electronic
transmission device or mailed first class, postage prepaid, certified United
States mail, return receipt requested, as follows:
27
<PAGE> 49
(a) If to Purchaser or LifeQuest, at:
LifeQuest Medical, Inc.
12961 Park Central, Suite 1300
San Antonio, Texas 78216
Attention: Randall K. Boatright
Facsimile No.: (210) 495-4441
With a copy to:
Fulbright & Jaworski L.L.P.
300 Convent Street, Suite 2200
San Antonio, Texas 78205
Attention: Phillip M. Renfro
Facsimile No.: (210) 270-7205
(b) If to Seller, at:
Dexterity Incorporated
1787 Sentry Parkway West, Bldg. Sixteen, Suite 220
Blue Bell Pennsylvania 19422
Attention: Christopher K. Black, President
Facsimile No.: (215) 641-9465
With a copy to:
Saul, Ewing, Remick & Saul, LLP
Centre Square West
1500 Market Street, 38th Floor
Philadelphia, PA 19102-2186
Attention: Donald Beckman
Facsimile No.: (215) 972-1821
provided that any party may change its address for notice by giving to the other
party written notice of such change. Any notice given under this Article 11
shall be effective (x) when delivered, if delivered personally, (y) 24 hours
after sending, if sent by telex or telegram or by facsimile or other similar
instantaneous electronic transmission device, and (z) 48 hours after mailing, if
mailed.
12. TERMINATION.
12.1 Termination of Agreement. Each of the Parties may terminate this
Agreement as provided below:
(a) LifeQuest and Seller may terminate this Agreement
by mutual written consent at any time prior to the Closing;
28
<PAGE> 50
(b) LifeQuest may terminate this Agreement by giving
written notice to Seller at any time prior to the Closing (i)
in the event the Seller has breached any Representation,
Warranty of Seller or covenant of Seller contained in this
Agreement in any material respect, LifeQuest has notified
Seller of the breach, and the breach has continued without
cure for a period of 15 days after the notice of breach or
(ii) if the Closing shall not have occurred on or before March
2, 1999, by reason of the failure of any condition precedent
under Section 9.1 hereof (unless the failure results primarily
from LifeQuest itself breaching any Representation, Warranty
or covenant of LifeQuest contained in this Agreement); and
(c) Seller may terminate this Agreement by giving
written notice to LifeQuest at any time prior to the Closing
(i) in the event LifeQuest has breached any representation,
warranty or covenant contained in this Agreement in any
material respect, Seller has notified LifeQuest of the breach,
and the breach has continued without cure for a period of 15
days after the notice of breach or (ii) if the Closing shall
not have occurred on or before March 2, 1999, by reason of the
failure of any condition precedent under Section 9.2 hereof
(unless the failure results primarily from Seller itself
breaching any Representation, Warranty or covenant of Seller
contained in this Agreement).
12.2 Effect of Termination. If any Party terminates this Agreement
pursuant to Section 12.1 herein, all rights and obligations of the Parties
hereunder shall terminate without any liability of any Party to any other Party
(except for any liability of any Party then in breach of its covenants
hereunder).
13. GENERAL PROVISIONS.
13.1 Governing Law; Interpretation; Section Headings. This Agreement
shall be governed by and construed and enforced in accordance with the laws of
the State of New York without regard to conflict-of-laws rules as applied in New
York. The section headings contained herein are for purposes of convenience only
and shall not be deemed to constitute a part of this Agreement or to affect the
meaning or interpretation of this Agreement in any way.
13.2 Severability. Should any provision of this Agreement be held
unenforceable or invalid under the laws of the United States of America or the
State of New York, or under any other applicable laws of any other jurisdiction,
then the parties hereto agree that such provision shall be deemed modified for
purposes of performance of this Agreement in such jurisdiction to the extent
necessary to render it lawful and enforceable, or if such a modification is not
possible without materially altering the intention of the parties hereto, then
such provision shall be severed herefrom for purposes of performance of this
Agreement in such jurisdiction. The validity of the remaining provisions of this
Agreement shall not be affected by any such modification or severance, except
that if any severance materially alters the intentions of the parties hereto as
expressed herein (a modification being permitted only if there is no material
alteration), then the parties hereto shall use commercially reasonable efforts
to agree to appropriate equitable amendments to this Agreement in light of such
severance.
29
<PAGE> 51
13.3 Entire Agreement. This Agreement sets forth the entire agreement
and understanding of the parties hereto with respect to the transactions
contemplated hereby and supersedes all prior agreements, arrangements and
understandings related to the subject matter hereof. No representation, promise,
inducement or statement of intention has been made by any party hereto which is
not embodied or referenced in this Agreement and no party hereto shall be bound
by or liable for any alleged representation, promise, inducement or statement of
intention not so set forth.
13.4 Binding Effect. All the terms, provisions, covenants and
conditions of this Agreement shall be binding upon and inure to the benefit of
and be enforceable by the parties hereto and their respective heirs, executors,
administrators, representatives, successors and assigns.
13.5 Assignment. This Agreement and the rights of the parties may be
assigned by any party hereto without the prior written consent of the other
parties hereto, provided that no such assignment shall relieve any party from
its obligations under this Agreement.
13.6 Amendment; Waiver. This Agreement may be amended, modified,
superseded or canceled, and any of the terms, provisions, representations,
warranties, covenants or conditions hereof may be waived, only by a written
instrument executed by all parties hereto, or, in the case of a waiver, by the
party waiving compliance. The failure of any party at any time or times to
require performance of any provision hereof shall in no manner affect the right
to enforce the same. No waiver by any party of any condition contained in this
Agreement, or of the breach of any term, provision, representation, warranty or
covenant contained in this Agreement, in any one or more instances, shall be
deemed to be or construed as a further or continuing waiver of any such
condition or breach, or as a waiver of any other condition or of the breach of
any other term, provision, representation, warranty or covenant.
13.7 Gender; Numbers. All references in this Agreement to the
masculine, feminine or neuter genders shall, where appropriate, be deemed to
include all other genders. All plurals used in this Agreement shall, where
appropriate, be deemed to be singular, and vice versa.
13.8 Counterparts. This Agreement may be executed simultaneously in two
or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. This Agreement
shall be binding when one or more counterparts hereof, individually or taken
together, shall bear the signatures of the parties reflected hereon as
signatories.
13.9 Telecopy Execution and Delivery. A facsimile, telecopy or other
reproduction of this Agreement may be executed by one or more parties hereto,
and an executed copy of this Agreement may be delivered by one or more parties
hereto by facsimile or similar instantaneous electronic transmission device
pursuant to which the signature of or on behalf of such party can be seen, and
such execution and delivery shall be considered valid, binding and effective for
all purposes. At the request of any party hereto, all parties hereto agree to
execute an original of this Agreement as well as any facsimile, telecopy or
other reproduction hereof.
30
<PAGE> 52
13.10 Expenses. In the event the transactions contemplated hereby are
not consummated, each of the parties will pay all costs and expenses of its or
his performance of and compliance with this Agreement.
13.11 Effect of Due Diligence. No investigation by or on behalf of
LifeQuest into the business, operations, prospects, assets or condition
(financial or otherwise) of the Seller shall diminish in any way the effect of
any representations or warranties made by Seller in this Agreement or shall
relieve Seller of any of its obligations under this Agreement.
13.12 Press Releases and Public Announcements. No Party shall issue any
press release or make any public announcement relating to the subject matter of
this Agreement prior to the Closing without the prior written approval of
LifeQuest and Seller; provided, however, that any Party may make any public
disclosure it believes in good faith is required by applicable law (in which
case the disclosing Party will use its reasonable best efforts to advise the
other Parties prior to making the disclosure).
13.13 No Third Party Beneficiaries. This Agreement shall not confer any
rights or remedies upon any Person other than the Parties and their respective
successors and permitted assigns.
13.14 Construction. The Parties have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the Parties and no presumption or burden of proof shall
arise favoring or disfavoring any Party by virtue of the authorship of any of
the provisions of this Agreement. Any reference to any federal, state, local, or
foreign statute or law shall be deemed also to refer to all rules and
regulations promulgated thereunder, unless the context requires otherwise. The
word "including" shall mean including without limitation. The Parties intend
that each representation, warranty and covenant contained herein shall have
independent significance. If any Party has breached any representation, warranty
or covenant contained herein in any respect, the fact that there exists another
representation, warranty or covenant relating to the same subject matter
(regardless of the relative levels of specificity) which the Party has not
breached shall not detract from or mitigate the fact that the Party is in breach
of the first representation, warranty or covenant.
13.15 Incorporation of Exhibits, and Schedules. The Exhibits, and
Schedules identified in this Agreement are incorporated herein by reference and
made a part hereof.
13.16 Specific Performance. Each of the Parties acknowledges and agrees
that the other Parties would be damaged irreparably in the event any of the
provisions of this Agreement are not performed in accordance with their specific
terms or otherwise are breached. Accordingly, each of the Parties agrees that
the other Parties shall be entitled to an injunction or injunctions to prevent
breaches of the provisions of this Agreement and to enforce specifically this
Agreement and the terms and provisions hereof in any action instituted in any
court of the United States or any state thereof having jurisdiction over the
Parties and the matter, in addition to any other remedy to which they may be
entitled, at law or in equity.
31
<PAGE> 53
IN WITNESS WHEREOF, the parties have executed this Plan of Merger and
Acquisition Agreement as of the date first above written.
LIFEQUEST:
LIFEQUEST MEDICAL, INC.
By:
--------------------------------------------
Richard A. Woodfield
President and Chief Executive Officer
SELLER:
DEXTERITY INCORPORATED
By:
--------------------------------------------
Christopher K. Black, President
32
<PAGE> 54
APPENDIX C
SECTION 262 OF THE DELAWARE GENERAL CORPORATION LAW
Section 262. Appraisal rights
(a) Any stockholder of a corporation of this State who holds shares of
stock on the date of the making of a demand pursuant to subsection (d) of this
section with respect to such shares, who continuously holds such shares through
the effective date of the merger or consolidation, who has otherwise complied
with subsection (d) of this section and who has neither voted in favor of the
merger or consolidation nor consented thereto in writing pursuant to Section 228
of this title shall be entitled to an appraisal by the Court of Chancery of the
fair value of the stockholder's shares of stock under the circumstances
described in subsections (b) and (c) of this section. As used in this section,
the word "stockholder" means a holder of record of stock in a stock corporation
and also a member of record of a nonstock corporation; the words "stock" and
"share" mean and include what is ordinarily meant by those words and also
membership or membership interest of a member of a nonstock corporation; and the
words "depository receipt" mean a receipt or other instrument issued by a
depository representing an interest in one or more shares, or fractions thereof,
solely of stock of a corporation which stock is deposited with the depository.
(b) Appraisal rights shall be available for the shares of any class or
series of stock of a constituent corporation in a merger or consolidation to be
effected pursuant to Section 251 (other than a merger effected pursuant to
Section 251(g) of this title), Section 252, Section 254, Section 257, Section
258, Section 263 or Section 264 of this title:
(1) Provided, however, that no appraisal rights under this
section shall be available for the shares of any class or series of
stock, which stock, or depository receipts in respect thereof, at the
record date fixed to determine the stockholders entitled to receive
notice of and to vote at the meeting of stockholders to act upon the
agreement of merger or consolidation, were either (i) listed on a
national securities exchange or designated as a national market system
security on an interdealer quotation system by the National Association
of Securities Dealers, Inc. or (ii) held of record by more than 2,000
holders; and further provided that no appraisal rights shall be
available for any shares of stock of the constituent corporation
surviving a merger if the merger did not require for its approval the
vote of the stockholders of the surviving corporation as provided in
subsection (f) of Section 251 of this title.
(2) Notwithstanding paragraph (1) of this subsection,
appraisal rights under this section shall be available for the shares
of any class or series of stock of a constituent corporation if the
holders thereof are required by the terms of an agreement of merger or
consolidation pursuant to Sections 251, 252, 254, 257, 258, 263 and 264
of this title to accept for such stock anything except:
<PAGE> 55
a. Shares of stock of the corporation surviving or
resulting from such merger or consolidation, or depository
receipts in respect thereof;
b. Shares of stock of any other corporation, or
depository receipts in respect thereof, which shares of stock
(or depository receipts in respect thereof) or depository
receipts at the effective date of the merger or consolidation
will be either listed on a national securities exchange or
designated as a national market system security on an
interdealer quotation system by the National Association of
Securities Dealers, Inc. or held of record by more than 2,000
holders;
c. Cash in lieu of fractional shares or fractional
depository receipts described in the foregoing subparagraphs
a. and b. of this paragraph; or
d. Any combination of the shares of stock, depository
receipts and cash in lieu of fractional shares or fractional
depository receipts described in the foregoing subparagraphs
a., b. and c. of this paragraph.
(3) In the event all of the stock of a subsidiary Delaware
corporation party to a merger effected under Section 253 of this title
is not owned by the parent corporation immediately prior to the merger,
appraisal rights shall be available for the shares of the subsidiary
Delaware corporation.
(c) Any corporation may provide in its certificate of incorporation
that appraisal rights under this section shall be available for the shares of
any class or series of its stock as a result of an amendment to its certificate
of incorporation, any merger or consolidation in which the corporation is a
constituent corporation or the sale of all or substantially all of the assets of
the corporation. If the certificate of incorporation contains such a provision,
the procedures of this section, including those set forth in subsections (d) and
(e) of this section, shall apply as nearly as is practicable.
(d) Appraisal rights shall be perfected as follows:
(1) If a proposed merger or consolidation for which appraisal
rights are provided under this section is to be submitted for approval
at a meeting of stockholders, the corporation, not less than 20 days
prior to the meeting, shall notify each of its stockholders who was
such on the record date for such meeting with respect to shares for
which appraisal rights are available pursuant to subsection (b) or (c)
hereof that appraisal rights are available for any or all of the shares
of the constituent corporations, and shall include in such notice a
copy of this section. Each stockholder electing to demand the appraisal
of such stockholder's shares shall deliver to the corporation, before
the taking of the vote on the merger or consolidation, a written demand
for appraisal of such stockholder's shares. Such demand will be
sufficient if it reasonably informs the corporation of the identity of
the stockholder and that the stockholder intends thereby to demand the
appraisal of such stockholder's shares. A proxy or vote against the
merger or consolidation shall not constitute such a demand. A
stockholder electing to take such action must do so by a separate
written demand as herein provided.
<PAGE> 56
Within 10 days after the effective date of such merger or
consolidation, the surviving or resulting corporation shall notify each
stockholder of each constituent corporation who has complied with this
subsection and has not voted in favor of or consented to the merger or
consolidation of the date that the merger or consolidation has become
effective; or
(2) If the merger or consolidation was approved pursuant to
Section 228 or Section 253 of this title, each constituent
corporation, either before the effective date of the merger or
consolidation or within ten days thereafter, shall notify each of the
holders of any class or series of stock of such constituent
corporation who are entitled to appraisal rights of the approval of the
merger or consolidation and that appraisal rights are available for any
or all shares of such class or series of stock of such constituent
corporation, and shall include in such notice a copy of this section;
provided that, if the notice is given on or after the effective date of
the merger or consolidation, such notice shall be given by the
surviving or resulting corporation to all such holders of any class or
series of stock of a constituent corporation that are entitled to
appraisal rights. Such notice may, and, if given on or after the
effective date of the merger or consolidation, shall, also notify such
stockholders of the effective date of the merger or consolidation. Any
stockholder entitled to appraisal rights may, within 20 days after the
date of mailing of such notice, demand in writing from the surviving or
resulting corporation the appraisal of such holder's shares. Such
demand will be sufficient if it reasonably informs the corporation of
the identity of the stockholder and that the stockholder intends
thereby to demand the appraisal of such holder's shares. If such notice
did not notify stockholders of the effective date of the merger or
consolidation, either (i) each such constituent corporation shall send
a second notice before the effective date of the merger or
consolidation notifying each of the holders of any class or series of
stock of such constituent corporation that are entitled to appraisal
rights of the effective date of the merger or consolidation or (ii) the
surviving or resulting corporation shall send such a second notice to
all such holders on or within 10 days after such effective date;
provided, however, that if such second notice is sent more than 20 days
following the sending of the first notice, such second notice need only
be sent to each stockholder who is entitled to appraisal rights and who
has demanded appraisal of such holder's shares in accordance with this
subsection. An affidavit of the secretary or assistant secretary or of
the transfer agent of the corporation that is required to give either
notice that such notice has been given shall, in the absence of fraud,
be prima facie evidence of the facts stated therein. For purposes of
determining the stockholders entitled to receive either notice, each
constituent corporation may fix, in advance, a record date that shall
be not more than 10 days prior to the date the notice is given,
provided, that if the notice is given on or after the effective date of
the merger or consolidation, the record date shall be such effective
date. If no record date is fixed and the notice is given prior to the
effective date, the record date shall be the close of business on the
day next preceding the day on which the notice is given.
(e) Within 120 days after the effective date of the merger or
consolidation, the surviving or resulting corporation or any stockholder who has
complied with subsections (a) and (d) hereof and who is otherwise entitled to
appraisal rights, may file a petition in the Court of Chancery demanding a
determination of the value of the stock of all such stockholders.
Notwithstanding the foregoing, at
<PAGE> 57
any time within 60 days after the effective date of the merger or consolidation,
any stockholder shall have the right to withdraw such stockholder's demand for
appraisal and to accept the terms offered upon the merger or consolidation.
Within 120 days after the effective date of the merger or consolidation, any
stockholder who has complied with the requirements of subsections (a) and (d)
hereof, upon written request, shall be entitled to receive from the corporation
surviving the merger or resulting from the consolidation a statement setting
forth the aggregate number of shares not voted in favor of the merger or
consolidation and with respect to which demands for appraisal have been received
and the aggregate number of holders of such shares. Such written statement shall
be mailed to the stockholder within 10 days after such stockholder's written
request for such a statement is received by the surviving or resulting
corporation or within 10 days after expiration of the period for delivery of
demands for appraisal under subsection (d) hereof, whichever is later.
(f) Upon the filing of any such petition by a stockholder, service of a
copy thereof shall be made upon the surviving or resulting corporation, which
shall within 20 days after such service file in the office of the Register in
Chancery in which the petition was filed a duly verified list containing the
names and addresses of all stockholders who have demanded payment for their
shares and with whom agreements as to the value of their shares have not been
reached by the surviving or resulting corporation. If the petition shall be
filed by the surviving or resulting corporation, the petition shall be
accompanied by such a duly verified list. The Register in Chancery, if so
ordered by the Court, shall give notice of the time and place fixed for the
hearing of such petition by registered or certified mail to the surviving or
resulting corporation and to the stockholders shown on the list at the addresses
therein stated. Such notice shall also be given by 1 or more publications at
least 1 week before the day of the hearing, in a newspaper of general
circulation published in the City of Wilmington, Delaware or such publication as
the Court deems advisable. The forms of the notices by mail and by publication
shall be approved by the Court, and the costs thereof shall be borne by the
surviving or resulting corporation.
(g) At the hearing on such petition, the Court shall determine the
stockholders who have complied with this section and who have become entitled to
appraisal rights. The Court may require the stockholders who have demanded an
appraisal for their shares and who hold stock represented by certificates to
submit their certificates of stock to the Register in Chancery for notation
thereon of the pendency of the appraisal proceedings; and if any stockholder
fails to comply with such direction, the Court may dismiss the proceedings as to
such stockholder.
(h) After determining the stockholders entitled to an appraisal, the
Court shall appraise the shares, determining their fair value exclusive of any
element of value arising from the accomplishment or expectation of the merger or
consolidation, together with a fair rate of interest, if any, to be paid upon
the amount determined to be the fair value. In determining such fair value, the
Court shall take into account all relevant factors. In determining the fair rate
of interest, the Court may consider all relevant factors, including the rate of
interest which the surviving or resulting corporation would have had to pay to
borrow money during the pendency of the proceeding. Upon application by the
surviving or resulting corporation or by any stockholder entitled to participate
in the appraisal proceeding, the Court may, in its discretion, permit discovery
or other pretrial proceedings and may proceed to trial upon the appraisal prior
to the final determination of the stockholder entitled to an
<PAGE> 58
appraisal. Any stockholder whose name appears on the list filed by the surviving
or resulting corporation pursuant to subsection (f) of this section and who has
submitted such stockholder's certificates of stock to the Register in Chancery,
if such is required, may participate fully in all proceedings until it is
finally determined that such stockholder is not entitled to appraisal rights
under this section.
(i) The Court shall direct the payment of the fair value of the shares,
together with interest, if any, by the surviving or resulting corporation to the
stockholders entitled thereto. Interest may be simple or compound, as the Court
may direct. Payment shall be so made to each such stockholder, in the case of
holders of uncertificated stock forthwith, and the case of holders of shares
represented by certificates upon the surrender to the corporation of the
certificates representing such stock. The Court's decree may be enforced as
other decrees in the Court of Chancery may be enforced, whether such surviving
or resulting corporation be a corporation of this State or of any state.
(j) The costs of the proceeding may be determined by the Court and
taxed upon the parties as the Court deems equitable in the circumstances. Upon
application of a stockholder, the Court may order all or a portion of the
expenses incurred by any stockholder in connection with the appraisal
proceeding, including, without limitation, reasonable attorney's fees and the
fees and expenses of experts, to be charged pro rata against the value of all
the shares entitled to an appraisal.
(k) From and after the effective date of the merger or consolidation,
no stockholder who has demanded appraisal rights as provided in subsection (d)
of this section shall be entitled to vote such stock for any purpose or to
receive payment of dividends or other distributions on the stock (except
dividends or other distributions payable to stockholders of record at a date
which is prior to the effective date of the merger or consolidation); provided,
however, that if no petition for an appraisal shall be filed within the time
provided in subsection (e) of this section, or if such stockholder shall deliver
to the surviving or resulting corporation a written withdrawal of such
stockholder's demand for an appraisal and an acceptance of the merger or
consolidation, either within 60 days after the effective date of the merger or
consolidation as provided in subsection (e) of this section or thereafter with
the written approval of the corporation, then the right of such stockholder to
an appraisal shall cease. Notwithstanding the foregoing, no appraisal proceeding
in the Court of Chancery shall be dismissed as to any stockholder without the
approval of the Court, and such approval may be conditioned upon such terms as
the Court deems just.
(l) The shares of the surviving or resulting corporation to which the
shares of such objecting stockholders would have been converted had they
assented to the merger or consolidation shall have the status of authorized and
unissued shares of the surviving or resulting corporation.
<PAGE> 59
LIFEQUEST MEDICAL, INC.
PROXY -- SPECIAL MEETING OF STOCKHOLDERS -- FEBRUARY 25, 1999
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
Please mark, sign, date and return in the enclosed envelope.
The undersigned stockholder of LifeQuest Medical, Inc. (the "Company")
P hereby appoints Richard A. Woodfield and Randall K. Boatright, or each of
R them, proxies of the undersigned with full power of substitution to vote at
O the Special Meeting of Stockholders of the Company to be held on Thursday,
X February 25, 1999, at 1:00 p.m., Eastern Standard Time, at the Company's
Y Atlanta offices, Fulton 400 Corporate Center, Suite 700, Roswell, Georgia,
and at any adjournment thereof, the number of votes which the undersigned
would be entitled to cast if personally present:
(1) Proposal to approve and adopt the terms of the Plan of
Merger and Acquisition Agreement dated December 18, 1998
between the Company and Dexterity Incorporated.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
(2) To consider and act upon any other matter which may
properly come before the meeting or any adjournment
thereof;
all as more particularly described in the Proxy Statement dated January
_____, 1999, relating to such meeting, receipt of which is hereby
acknowledged.
This proxy when properly executed will be voted in the manner directed
herein by the undersigned shareholder. If no direction is made, this proxy
will be voted FOR Proposal 1.
--------------------------------------
--------------------------------------
Signature of Stockholder(s)
Please sign your name exactly as it
appears hereon. Joint owners must each
sign. When signing as attorney,
executor, administrator, trustee or
guardian, please give your full title as
it appears hereon.
Dated __________________________, 1999.
